<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
	<head>
		<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
		<meta http-equiv="Content-Style-Type" content="text/css" />
		<meta name="generator" content="MediaWiki 1.15alpha" />
		<meta name="keywords" content="Warfarin,Articles with unsourced statements since January 2009,Antithrombotics,1,3-indandione,1996,ADP receptor,ATC code B01,Abciximab,Acenocoumarol,Adverse drug reaction,African American" />
		<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Warfarin&amp;action=edit" />
		<link rel="edit" title="Edit this page" href="/w/index.php?title=Warfarin&amp;action=edit" />
		<link rel="apple-touch-icon" href="http://en.wikipedia.org/apple-touch-icon.png" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)" />
		<link rel="copyright" href="http://www.gnu.org/copyleft/fdl.html" />
		<link rel="alternate" type="application/rss+xml" title="Wikipedia RSS Feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=rss" />
		<link rel="alternate" type="application/atom+xml" title="Wikipedia Atom Feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=atom" />
		<title>Warfarin - Wikipedia, the free encyclopedia</title>
		<link rel="stylesheet" href="/skins-1.5/common/shared.css?207xx" type="text/css" media="screen" />
		<link rel="stylesheet" href="/skins-1.5/common/commonPrint.css?207xx" type="text/css" media="print" />
		<link rel="stylesheet" href="/skins-1.5/monobook/main.css?207xx" type="text/css" media="screen" />
		<link rel="stylesheet" href="/skins-1.5/chick/main.css?207xx" type="text/css" media="handheld" />
		<!--[if lt IE 5.5000]><link rel="stylesheet" href="/skins-1.5/monobook/IE50Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<!--[if IE 5.5000]><link rel="stylesheet" href="/skins-1.5/monobook/IE55Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<!--[if IE 6]><link rel="stylesheet" href="/skins-1.5/monobook/IE60Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<!--[if IE 7]><link rel="stylesheet" href="/skins-1.5/monobook/IE70Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Common.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" />
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Print.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" media="print" />
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Handheld.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" media="handheld" />
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Monobook.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" />
		<link rel="stylesheet" href="/w/index.php?title=-&amp;action=raw&amp;maxage=2678400&amp;gen=css" type="text/css" />
		<!--[if lt IE 7]><script type="text/javascript" src="/skins-1.5/common/IEFixes.js?207xx"></script>
		<meta http-equiv="imagetoolbar" content="no" /><![endif]-->

		<script type= "text/javascript">/*<![CDATA[*/
		var skin = "monobook";
		var stylepath = "/skins-1.5";
		var wgArticlePath = "/wiki/$1";
		var wgScriptPath = "/w";
		var wgScript = "/w/index.php";
		var wgVariantArticlePath = false;
		var wgActionPaths = {};
		var wgServer = "http://en.wikipedia.org";
		var wgCanonicalNamespace = "";
		var wgCanonicalSpecialPageName = false;
		var wgNamespaceNumber = 0;
		var wgPageName = "Warfarin";
		var wgTitle = "Warfarin";
		var wgAction = "view";
		var wgArticleId = "238097";
		var wgIsArticle = true;
		var wgUserName = null;
		var wgUserGroups = null;
		var wgUserLanguage = "en";
		var wgContentLanguage = "en";
		var wgBreakFrames = false;
		var wgCurRevisionId = 281584235;
		var wgVersion = "1.15alpha";
		var wgEnableAPI = true;
		var wgEnableWriteAPI = true;
		var wgSeparatorTransformTable = ["", ""];
		var wgDigitTransformTable = ["", ""];
		var wgMWSuggestTemplate = "http://en.wikipedia.org/w/api.php?action=opensearch\x26search={searchTerms}\x26namespace={namespaces}\x26suggest";
		var wgDBname = "enwiki";
		var wgSearchNamespaces = [0];
		var wgMWSuggestMessages = ["with suggestions", "no suggestions"];
		var wgRestrictionEdit = [];
		var wgRestrictionMove = [];
		/*]]>*/</script>

		<script type="text/javascript" src="/skins-1.5/common/wikibits.js?207xx"><!-- wikibits js --></script>
		<!-- Head Scripts -->
		<script type="text/javascript" src="/skins-1.5/common/ajax.js?207xx"></script>
		<script type="text/javascript" src="/skins-1.5/common/mwsuggest.js?207xx"></script>
<script type="text/javascript">/*<![CDATA[*/
var wgNotice='';var wgNoticeLocal='';
/*]]>*/</script>		<script type="text/javascript" src="http://upload.wikimedia.org/centralnotice/wikipedia/en/centralnotice.js?207xx"></script>
		<script type="text/javascript" src="/w/index.php?title=-&amp;action=raw&amp;gen=js&amp;useskin=monobook"><!-- site js --></script>
	</head>
<body class="mediawiki ltr ns-0 ns-subject page-Warfarin skin-monobook">
	<div id="globalWrapper">
		<div id="column-content">
	<div id="content">
		<a name="top" id="top"></a>
		<div id="siteNotice"><script type='text/javascript'>if (wgNotice != '') document.writeln(wgNotice);</script></div>		<h1 id="firstHeading" class="firstHeading">Warfarin</h1>
		<div id="bodyContent">
			<h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
			<div id="contentSub"></div>
									<div id="jump-to-nav">Jump to: <a href="#column-one">navigation</a>, <a href="#searchInput">search</a></div>			<!-- start content -->
			<table id="drugInfoBox" style="float: right; clear: right; margin: 0 0 0.5em 1em; background: #ffffff;" class="toccolours" border="0" cellpadding="1" align="right" width="280">
<tr>
<td align="center" colspan="2"><a href="/wiki/File:Warfarin.svg" class="image" title="Warfarin.svg"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/7/7e/Warfarin.svg/220px-Warfarin.svg.png" width="220" height="163" border="0" /></a></td>
</tr>
<tr>
<td align="center" colspan="2"><a href="/wiki/File:Warfarin-from-xtal-3D-balls.png" class="image" title="Warfarin-from-xtal-3D-balls.png"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/b/bf/Warfarin-from-xtal-3D-balls.png/220px-Warfarin-from-xtal-3D-balls.png" width="220" height="158" border="0" /></a></td>
</tr>
<tr>
<td align="center" colspan="2">
<div style="font-size:medium; line-height:167%;">Warfarin</div>
</td>
</tr>
<tr>
<td align="center" colspan="2" bgcolor="#DDDDDD"><b>Systematic (<a href="/wiki/International_Union_of_Pure_and_Applied_Chemistry_nomenclature" title="International Union of Pure and Applied Chemistry nomenclature" class="mw-redirect">IUPAC</a>) name</b></td>
</tr>
<tr>
<td bgcolor="#EEEEEE" style="text-align: center; vertical-align: top;" colspan="2"><span style="font-size:11px">(RS)-4-hydroxy- 3-(3- oxo- 1-phenylbutyl)- 2<i>H</i>- chromen- 2-one</span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Identifiers</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" width="90"><a href="/wiki/CAS_registry_number" title="CAS registry number">CAS number</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?term=81-81-2&amp;rn=1" class="external text" title="http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?term=81-81-2&amp;rn=1" rel="nofollow">81-81-2</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/Anatomical_Therapeutic_Chemical_Classification_System" title="Anatomical Therapeutic Chemical Classification System">ATC code</a></td>
<td bgcolor="#EEEEEE"><a href="/wiki/ATC_code_B01" title="ATC code B01">B01</a><span class="reflink plainlinksneverexpand"><a href="http://www.whocc.no/atcddd/indexdatabase/index.php?query=B01AA03" class="external text" title="http://www.whocc.no/atcddd/indexdatabase/index.php?query=B01AA03" rel="nofollow">AA03</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/PubChem" title="PubChem">PubChem</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6691" class="external text" title="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6691" rel="nofollow">6691</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/DrugBank" title="DrugBank">DrugBank</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.drugbank.ca/cgi-bin/show_drug.cgi?CARD=APRD00341" class="external text" title="http://www.drugbank.ca/cgi-bin/show_drug.cgi?CARD=APRD00341" rel="nofollow">APRD00341</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/ChemSpider" title="ChemSpider">ChemSpider</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.chemspider.com/Chemical-Structure.10442445" class="external text" title="http://www.chemspider.com/Chemical-Structure.10442445" rel="nofollow">10442445</a></span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Chemical data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/Chemical_formula" title="Chemical formula">Formula</a></td>
<td bgcolor="#EEEEEE"><a href="/wiki/Carbon" title="Carbon"><span style="color: rgb(000,000,000); font-weight: bold;">C</span></a><sub>19</sub><a href="/wiki/Hydrogen" title="Hydrogen"><span style="color: rgb(77,77,77); font-weight: bold;">H</span></a><sub>16</sub><a href="/wiki/Oxygen" title="Oxygen"><span style="color: rgb(116,35,35); font-weight: bold;">O</span></a><sub>4</sub><sup>&#160;</sup></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/Molecular_mass" title="Molecular mass">Mol. mass</a></td>
<td bgcolor="#EEEEEE">308.33 g/mol</td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/Simplified_molecular_input_line_entry_specification" title="Simplified molecular input line entry specification">SMILES</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.emolecules.com/cgi-bin/search?t=ex&amp;q=CC%28%3DO%29CC%28c1ccccc1%29C2%3DC%28O%29c3ccccc3OC2%3DO" class="external text" title="http://www.emolecules.com/cgi-bin/search?t=ex&amp;q=CC%28%3DO%29CC%28c1ccccc1%29C2%3DC%28O%29c3ccccc3OC2%3DO" rel="nofollow">eMolecules</a></span> &amp; <span class="reflink plainlinksneverexpand"><a href="http://pubchem.ncbi.nlm.nih.gov/search/?smarts=CC%28%3DO%29CC%28c1ccccc1%29C2%3DC%28O%29c3ccccc3OC2%3DO" class="external text" title="http://pubchem.ncbi.nlm.nih.gov/search/?smarts=CC%28%3DO%29CC%28c1ccccc1%29C2%3DC%28O%29c3ccccc3OC2%3DO" rel="nofollow">PubChem</a></span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Pharmacokinetic data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Bioavailability" title="Bioavailability">Bioavailability</a></td>
<td bgcolor="#EEEEEE">100%</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Plasma_protein_binding" title="Plasma protein binding">Protein binding</a></td>
<td bgcolor="#EEEEEE">99.5%</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Drug_metabolism" title="Drug metabolism">Metabolism</a></td>
<td bgcolor="#EEEEEE">Hepatic: <a href="/wiki/CYP2C9" title="CYP2C9">CYP2C9</a>, <a href="/wiki/CYP2C19" title="CYP2C19">2C19</a>, 2C8, 2C18, <a href="/wiki/CYP1A2" title="CYP1A2">1A2</a> and <a href="/wiki/CYP3A4" title="CYP3A4">3A4</a></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Biological_half-life" title="Biological half-life">Half life</a></td>
<td bgcolor="#EEEEEE">2.5 days</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Excretion" title="Excretion">Excretion</a></td>
<td bgcolor="#EEEEEE"><a href="/wiki/Kidney" title="Kidney">Renal</a> (92%)</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Therapeutic considerations</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Pregnancy_category" title="Pregnancy category">Pregnancy cat.</a></td>
<td bgcolor="#EEEEEE">
<p>D<small>(<a href="/wiki/Australia" title="Australia">AU</a>)</small> X<small>(<a href="/wiki/United_States" title="United States">US</a>)</small></p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Regulation_of_therapeutic_goods" title="Regulation of therapeutic goods">Legal status</a></td>
<td bgcolor="#EEEEEE">
<p><a href="/wiki/Standard_for_the_Uniform_Scheduling_of_Drugs_and_Poisons#Schedule_4_Prescription_Only_Medicine" title="Standard for the Uniform Scheduling of Drugs and Poisons">Prescription Only (S4)</a><small>(<a href="/wiki/Australia" title="Australia">AU</a>)</small> <a href="/wiki/Prescription_drug" title="Prescription drug">POM</a><small>(<a href="/wiki/United_Kingdom" title="United Kingdom">UK</a>)</small> <a href="/wiki/Prescription_drug" title="Prescription drug"><span class="Unicode">℞</span><small>-only</small></a><small>(<a href="/wiki/United_States" title="United States">US</a>)</small></p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Route_of_administration" title="Route of administration">Routes</a></td>
<td bgcolor="#EEEEEE">Oral or <a href="/wiki/Intravenous_therapy" title="Intravenous therapy">intravenous</a></td>
</tr>
</table>
<p><b>Warfarin</b> (also known under the brand names <b>Coumadin</b>, <b>Jantoven</b>, <b>Marevan</b>, and <b>Waran</b>) is an <a href="/wiki/Anticoagulant" title="Anticoagulant">anticoagulant</a>. It was initially marketed as a pesticide against rats and mice, and is still popular for this purpose, although more potent poisons such as <a href="/wiki/Brodifacoum" title="Brodifacoum">brodifacoum</a> have since been developed. A few years after its introduction, warfarin was found to be effective and relatively safe for <a href="/wiki/Prophylaxis" title="Prophylaxis">preventing</a> <a href="/wiki/Thrombosis" title="Thrombosis">thrombosis</a> and <a href="/wiki/Embolism" title="Embolism">embolism</a> (abnormal formation and migration of blood clots) in many disorders. It was approved for use as a medication in the early 1950s, and has remained popular ever since; warfarin is the most widely prescribed anticoagulant drug in <a href="/wiki/North_America" title="North America">North America</a>.<sup id="cite_ref-Holbrook_0-0" class="reference"><a href="#cite_note-Holbrook-0" title=""><span>[</span>1<span>]</span></a></sup> Despite its effectiveness, treatment with warfarin has several shortcomings. Many commonly used medications <a href="/wiki/Drug_interaction" title="Drug interaction">interact</a> with warfarin, as do some foods and its activity has to be monitored by frequent <a href="/wiki/Blood_test" title="Blood test">blood testing</a> for the <a href="/wiki/Prothrombin_time" title="Prothrombin time">international normalized ratio</a> (INR) to ensure an adequate yet safe dose is taken.<sup id="cite_ref-Ansell_1-0" class="reference"><a href="#cite_note-Ansell-1" title=""><span>[</span>2<span>]</span></a></sup></p>
<p>Warfarin is a synthetic derivative of <a href="/wiki/Coumarin" title="Coumarin">coumarin</a>, a chemical found naturally in many <a href="/wiki/Plant" title="Plant">plants</a>, notably <a href="/wiki/Woodruff" title="Woodruff">woodruff</a> (<i>Galium odoratum</i>, <a href="/wiki/Rubiaceae" title="Rubiaceae">Rubiaceae</a>), and at lower levels in <a href="/wiki/Licorice" title="Licorice" class="mw-redirect">licorice</a>, <a href="/wiki/Lavender" title="Lavender">lavender</a>, and various other species. Warfarin and related coumarins decrease blood <a href="/wiki/Coagulation" title="Coagulation">coagulation</a> by inhibiting <a href="/wiki/Vitamin_K_epoxide_reductase" title="Vitamin K epoxide reductase">vitamin K epoxide reductase</a>, an <a href="/wiki/Enzyme" title="Enzyme">enzyme</a> that recycles <a href="/wiki/Oxidation" title="Oxidation" class="mw-redirect">oxidated</a> <a href="/wiki/Vitamin_K" title="Vitamin K">vitamin K</a> to its reduced form after it has participated in the <a href="/wiki/Carboxylation" title="Carboxylation">carboxylation</a> of several blood coagulation proteins, mainly <a href="/wiki/Prothrombin" title="Prothrombin" class="mw-redirect">prothrombin</a> and <a href="/wiki/Factor_VII" title="Factor VII">factor VII</a>. For this reason, drugs in this class are also referred to as <a href="/wiki/Anticoagulant#Vitamin_K_antagonists" title="Anticoagulant">vitamin K antagonists</a>.<sup id="cite_ref-Ansell_1-1" class="reference"><a href="#cite_note-Ansell-1" title=""><span>[</span>2<span>]</span></a></sup></p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#History"><span class="tocnumber">1</span> <span class="toctext">History</span></a></li>
<li class="toclevel-1"><a href="#Therapeutic_uses"><span class="tocnumber">2</span> <span class="toctext">Therapeutic uses</span></a></li>
<li class="toclevel-1"><a href="#Contraindications"><span class="tocnumber">3</span> <span class="toctext">Contraindications</span></a>
<ul>
<li class="toclevel-2"><a href="#Pregnancy"><span class="tocnumber">3.1</span> <span class="toctext">Pregnancy</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Adverse_effects"><span class="tocnumber">4</span> <span class="toctext">Adverse effects</span></a>
<ul>
<li class="toclevel-2"><a href="#Hemorrhage"><span class="tocnumber">4.1</span> <span class="toctext">Hemorrhage</span></a></li>
<li class="toclevel-2"><a href="#Warfarin_necrosis"><span class="tocnumber">4.2</span> <span class="toctext">Warfarin necrosis</span></a></li>
<li class="toclevel-2"><a href="#Osteoporosis"><span class="tocnumber">4.3</span> <span class="toctext">Osteoporosis</span></a></li>
<li class="toclevel-2"><a href="#Purple_toe_syndrome"><span class="tocnumber">4.4</span> <span class="toctext">Purple toe syndrome</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Pharmacology"><span class="tocnumber">5</span> <span class="toctext">Pharmacology</span></a>
<ul>
<li class="toclevel-2"><a href="#Pharmacokinetics"><span class="tocnumber">5.1</span> <span class="toctext">Pharmacokinetics</span></a></li>
<li class="toclevel-2"><a href="#Mechanism_of_action"><span class="tocnumber">5.2</span> <span class="toctext">Mechanism of action</span></a></li>
<li class="toclevel-2"><a href="#Antagonism"><span class="tocnumber">5.3</span> <span class="toctext">Antagonism</span></a></li>
<li class="toclevel-2"><a href="#Pharmacogenomics"><span class="tocnumber">5.4</span> <span class="toctext">Pharmacogenomics</span></a>
<ul>
<li class="toclevel-3"><a href="#VKORC1"><span class="tocnumber">5.4.1</span> <span class="toctext">VKORC1</span></a></li>
<li class="toclevel-3"><a href="#CYP2C9"><span class="tocnumber">5.4.2</span> <span class="toctext">CYP2C9</span></a></li>
</ul>
</li>
<li class="toclevel-2"><a href="#Loading_regimens"><span class="tocnumber">5.5</span> <span class="toctext">Loading regimens</span></a></li>
<li class="toclevel-2"><a href="#Adjusting_the_maintenance_dose"><span class="tocnumber">5.6</span> <span class="toctext">Adjusting the maintenance dose</span></a></li>
<li class="toclevel-2"><a href="#Self-testing_and_home_monitoring"><span class="tocnumber">5.7</span> <span class="toctext">Self-testing and home monitoring</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Drug_interactions"><span class="tocnumber">6</span> <span class="toctext">Drug interactions</span></a></li>
<li class="toclevel-1"><a href="#Use_as_a_pesticide"><span class="tocnumber">7</span> <span class="toctext">Use as a pesticide</span></a></li>
<li class="toclevel-1"><a href="#References"><span class="tocnumber">8</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1"><a href="#External_links"><span class="tocnumber">9</span> <span class="toctext">External links</span></a></li>
</ul>
</td>
</tr>
</table>
<script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script>
<p><a name="History" id="History"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=1" title="Edit section: History">edit</a>]</span> <span class="mw-headline">History</span></h2>
<p>The early 1920s saw the outbreak of a previously unrecognized disease of <a href="/wiki/Cattle" title="Cattle">cattle</a> in the northern United States and Canada. Cattle would die of uncontrollable <a href="/wiki/Bleeding" title="Bleeding">bleeding</a> from very minor injuries, or sometimes drop dead of internal hemorrhage with no external signs of injury. In 1921, Frank Schofield, a Canadian <a href="/wiki/Veterinarian" title="Veterinarian">veterinarian</a>, determined that the cattle were ingesting moldy <a href="/wiki/Silage" title="Silage">silage</a> made from <a href="/wiki/Sweet_clover" title="Sweet clover" class="mw-redirect">sweet clover</a> that functioned as a potent anticoagulant.<sup id="cite_ref-2" class="reference"><a href="#cite_note-2" title=""><span>[</span>3<span>]</span></a></sup> In 1929, North Dakota veterinarian Dr L.M. Roderick demonstrated that the condition was due to a lack of functioning <a href="/wiki/Prothrombin" title="Prothrombin" class="mw-redirect">prothrombin</a>.<sup id="cite_ref-3" class="reference"><a href="#cite_note-3" title=""><span>[</span>4<span>]</span></a></sup></p>
<p>The identity of the anticoagulant substance in moldy sweet clover remained a mystery until 1940 when <a href="/wiki/Karl_Paul_Link" title="Karl Paul Link">Karl Paul Link</a> and his lab of chemists working at the <a href="/wiki/University_of_Wisconsin-Madison" title="University of Wisconsin-Madison">University of Wisconsin</a> set out to isolate and characterize the hemorrhagic agent from the spoiled hay. It ended up taking 5 years for Link's student Harold A. Campbell to recover 6 mg of crystalline anticoagulant. Next, Link's student Mark A. Stahmann took over the project and initiated a large scale extraction, isolating 1.8 g of recrystallized anticoagulant in about 4 months. This was enough material for Stahmann and Charles F. Huebner to check their results against Campbell's and to thoroughly characterize the compound. Through degradation experiments they established that the anticoagulant was 3,3'-methylenebis-(4-hydroxycoumarin), which they later named <a href="/wiki/Dicoumarol" title="Dicoumarol">dicoumarol</a>. They confirmed their results by synthesizing dicumarol and proving that it was identical to the naturally occurring agent.<sup id="cite_ref-4" class="reference"><a href="#cite_note-4" title=""><span>[</span>5<span>]</span></a></sup> Over the next few years, numerous similar chemicals were found to have the same anticoagulant properties. The first of these to be widely commercialized was dicoumarol, patented in 1941. Link continued working on developing more potent coumarin-based anticoagulants for use as <a href="/wiki/Rodenticide" title="Rodenticide">rodent poisons</a>, resulting in warfarin in 1948. (The name warfarin stems from the acronym <i>WARF</i>, for <i><a href="/wiki/Wisconsin_Alumni_Research_Foundation" title="Wisconsin Alumni Research Foundation">Wisconsin Alumni Research Foundation</a></i> + the ending <i>-arin</i> indicating its link with coumarin.) Warfarin was first registered for use as a rodenticide in the US in 1948, and was immediately popular; although it was developed by Link, the WARF financially supported the research and was assigned the patent.<sup id="cite_ref-pmid13619027_5-0" class="reference"><a href="#cite_note-pmid13619027-5" title=""><span>[</span>6<span>]</span></a></sup></p>
<p>After an incident in 1951, where a <a href="/wiki/United_States_Army" title="United States Army">US Army</a> inductee unsuccessfully attempted suicide with warfarin and recovered fully,<sup id="cite_ref-pmid13619027_5-1" class="reference"><a href="#cite_note-pmid13619027-5" title=""><span>[</span>6<span>]</span></a></sup> studies began in the use of warfarin as a therapeutic anticoagulant. It was found to be generally superior to dicoumarol, and in 1954 was approved for medical use in humans. A famous early recipient of warfarin was US president <a href="/wiki/Dwight_Eisenhower" title="Dwight Eisenhower" class="mw-redirect">Dwight Eisenhower</a>, who was prescribed the drug after having a <a href="/wiki/Myocardial_infarction" title="Myocardial infarction">heart attack</a> in 1955.<sup id="cite_ref-pmid13619027_5-2" class="reference"><a href="#cite_note-pmid13619027-5" title=""><span>[</span>6<span>]</span></a></sup></p>
<p>The exact <a href="/wiki/Mechanism_of_action" title="Mechanism of action">mechanism of action</a> remained unknown until it was demonstrated, in 1978, that warfarin <a href="/wiki/Enzyme_inhibitor" title="Enzyme inhibitor">inhibits</a> the enzyme <a href="/wiki/Vitamin_K_epoxide_reductase" title="Vitamin K epoxide reductase">epoxide reductase</a> and hence interferes with vitamin K metabolism.<sup id="cite_ref-Whitlon_6-0" class="reference"><a href="#cite_note-Whitlon-6" title=""><span>[</span>7<span>]</span></a></sup></p>
<p>A 2003 theory posits that warfarin was used by a conspiracy of <a href="/wiki/Lavrenty_Beria" title="Lavrenty Beria" class="mw-redirect">Lavrenty Beria</a>, <a href="/wiki/Nikita_Khrushchev" title="Nikita Khrushchev">Nikita Khrushchev</a> and others to poison Soviet leader <a href="/wiki/Joseph_Stalin" title="Joseph Stalin">Joseph Stalin</a>. Warfarin is tasteless and colorless, and produces symptoms similar to those that Stalin exhibited.<sup id="cite_ref-7" class="reference"><a href="#cite_note-7" title=""><span>[</span>8<span>]</span></a></sup></p>
<p><a name="Therapeutic_uses" id="Therapeutic_uses"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=2" title="Edit section: Therapeutic uses">edit</a>]</span> <span class="mw-headline">Therapeutic uses</span></h2>
<p>Warfarin is prescribed to people with an increased tendency for <a href="/wiki/Thrombosis" title="Thrombosis">thrombosis</a> or as secondary prophylaxis (prevention of further episodes) in those individuals that have already formed a blood clot (<a href="/wiki/Thrombus" title="Thrombus">thrombus</a>). Warfarin treatment can help prevent formation of future blood clots and help reduce the risk of <a href="/wiki/Embolism" title="Embolism">embolism</a> (migration of a thrombus to a spot where it blocks blood supply to a vital organ). Common clinical indications for warfarin use are <a href="/wiki/Atrial_fibrillation" title="Atrial fibrillation">atrial fibrillation</a>, the presence of <a href="/wiki/Artificial_heart_valve" title="Artificial heart valve">artificial heart valves</a>, <a href="/wiki/Deep_venous_thrombosis" title="Deep venous thrombosis" class="mw-redirect">deep venous thrombosis</a>, <a href="/wiki/Pulmonary_embolism" title="Pulmonary embolism">pulmonary embolism</a>, <a href="/wiki/Antiphospholipid_syndrome" title="Antiphospholipid syndrome">antiphospholipid syndrome</a> and, occasionally, after heart attacks (<a href="/wiki/Myocardial_infarction" title="Myocardial infarction">myocardial infarction</a>).<sup id="cite_ref-Hirsh_8-0" class="reference"><a href="#cite_note-Hirsh-8" title=""><span>[</span>9<span>]</span></a></sup></p>
<p>Dosing of warfarin is complicated by the fact that it is known to <a href="/wiki/Drug_interaction" title="Drug interaction">interact</a> with many commonly-used medications and even with chemicals that may be present in certain foods.<sup id="cite_ref-Holbrook_0-1" class="reference"><a href="#cite_note-Holbrook-0" title=""><span>[</span>1<span>]</span></a></sup> These interactions may enhance or reduce warfarin's anticoagulation effect. In order to optimize the therapeutic effect without risking dangerous side effects such as bleeding, close monitoring of the degree of anticoagulation is required by blood testing (<a href="/wiki/Prothrombin_time" title="Prothrombin time">INR</a>). During the initial stage of treatment, checking may be required daily; intervals between tests can be lengthened if the patient manages stable therapeutic INR levels on an unchanged warfarin dose.<sup id="cite_ref-Hirsh_8-1" class="reference"><a href="#cite_note-Hirsh-8" title=""><span>[</span>9<span>]</span></a></sup></p>
<p>When initiating warfarin therapy ("warfarinization"), the doctor will decide how strong the anticoagulant therapy needs to be. The target INR level will vary from case to case depending on the clinical indicators, but tends to be 2–3 in most conditions. In particular, target INR may be 2.5–3.5 (or even 3.0–4.5) in patients with one or more <a href="/wiki/Artificial_heart_valve#Mechanical_valves" title="Artificial heart valve">mechanical heart valves</a>.<sup id="cite_ref-9" class="reference"><a href="#cite_note-9" title=""><span>[</span>10<span>]</span></a></sup></p>
<p>In some countries, other coumarins are used instead of warfarin, such as <a href="/wiki/Acenocoumarol" title="Acenocoumarol">acenocoumarol</a> and <a href="/wiki/Phenprocoumon" title="Phenprocoumon">phenprocoumon</a>. These have a shorter (acenocoumarol) or longer (phenprocoumon) <a href="/wiki/Biological_half-life" title="Biological half-life">half-life</a>, and are not completely interchangeable with warfarin. The oral anticoagulant <a href="/wiki/Ximelagatran" title="Ximelagatran">ximelagatran</a> (trade name Exanta) was expected to replace warfarin to a large degree when introduced; however, reports of <a href="/wiki/Hepatotoxicity" title="Hepatotoxicity">hepatotoxicity</a> (liver damage) prompted its manufacturer to withdraw it from further development. Other drugs offering the efficacy of warfarin without a need for monitoring, such as <a href="/wiki/Dabigatran" title="Dabigatran">dabigatran</a> and <a href="/wiki/Rivaroxaban" title="Rivaroxaban">rivaroxaban</a>, are under development.<sup id="cite_ref-10" class="reference"><a href="#cite_note-10" title=""><span>[</span>11<span>]</span></a></sup></p>
<p><a name="Contraindications" id="Contraindications"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=3" title="Edit section: Contraindications">edit</a>]</span> <span class="mw-headline">Contraindications</span></h2>
<p><a name="Pregnancy" id="Pregnancy"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=4" title="Edit section: Pregnancy">edit</a>]</span> <span class="mw-headline">Pregnancy</span></h3>
<div class="rellink boilerplate further">Further information: <a href="/wiki/Anticoagulation_in_pregnancy" title="Anticoagulation in pregnancy">Anticoagulation in pregnancy</a></div>
<p>Warfarin is <a href="/wiki/Contraindication" title="Contraindication">contraindicated</a> in pregnancy, as it passes through the <a href="/wiki/Placenta" title="Placenta">placental</a> barrier and may cause bleeding in the fetus; warfarin use during pregnancy is commonly associated with <a href="/wiki/Miscarriage" title="Miscarriage">spontaneous abortion</a>, <a href="/wiki/Stillbirth" title="Stillbirth">stillbirth</a>, <a href="/wiki/Perinatal_mortality#Neonatal_mortality" title="Perinatal mortality">neonatal death</a>, and <a href="/wiki/Preterm_birth" title="Preterm birth">preterm birth</a>.<sup id="cite_ref-HDT_11-0" class="reference"><a href="#cite_note-HDT-11" title=""><span>[</span>12<span>]</span></a></sup> Coumarins (such as warfarin) are also <a href="/wiki/Teratogen" title="Teratogen" class="mw-redirect">teratogens</a>, that is, they cause <a href="/wiki/Birth_defect" title="Birth defect" class="mw-redirect">birth defects</a>; the incidence of birth defects in infants exposed to warfarin <i><a href="/wiki/In_utero" title="In utero">in utero</a></i> appears to be around 5%, although higher figures (up to 30%) have been reported in some studies.<sup id="cite_ref-Loftus_12-0" class="reference"><a href="#cite_note-Loftus-12" title=""><span>[</span>13<span>]</span></a></sup> Depending on when exposure occurs during pregnancy, two distinct combinations of congenital abnormalities can arise.<sup id="cite_ref-HDT_11-1" class="reference"><a href="#cite_note-HDT-11" title=""><span>[</span>12<span>]</span></a></sup></p>
<p>When warfarin (or another coumarin derivative) is given during the first trimester—particularly between the sixth and ninth weeks of pregnancy—a constellation of birth defects known variously as <a href="/wiki/Fetal_warfarin_syndrome" title="Fetal warfarin syndrome" class="mw-redirect">fetal warfarin syndrome</a> (FWS), <i>warfarin embryopathy</i>, or <i>coumarin embryopathy</i> can occur. FWS is characterized mainly by <a href="/wiki/Skeletal" title="Skeletal" class="mw-redirect">skeletal</a> abnormalities, which include nasal hypoplasia, a depressed or narrowed nasal bridge, <a href="/wiki/Scoliosis" title="Scoliosis">scoliosis</a>, and <a href="/wiki/Calcification" title="Calcification">calcifications</a> in the <a href="/wiki/Vertebral_column" title="Vertebral column">vertebral column</a>, <a href="/wiki/Femur" title="Femur">femur</a>, and <a href="/wiki/Calcaneus" title="Calcaneus">heel bone</a> which show a peculiar stippled appearance on <a href="/wiki/Medical_radiography" title="Medical radiography">X-rays</a>. <a href="/wiki/Dysmelia" title="Dysmelia">Limb abnormalities</a>, such as <a href="/wiki/Brachydactyly" title="Brachydactyly">brachydactyly</a> (unusually short fingers and toes) or underdeveloped extremities, can also occur.<sup id="cite_ref-HDT_11-2" class="reference"><a href="#cite_note-HDT-11" title=""><span>[</span>12<span>]</span></a></sup><sup id="cite_ref-Loftus_12-1" class="reference"><a href="#cite_note-Loftus-12" title=""><span>[</span>13<span>]</span></a></sup> Common non-skeletal features of FWS include <a href="/wiki/Low_birth_weight" title="Low birth weight" class="mw-redirect">low birth weight</a> and <a href="/wiki/Developmental_disability" title="Developmental disability">developmental disabilities</a>.<sup id="cite_ref-HDT_11-3" class="reference"><a href="#cite_note-HDT-11" title=""><span>[</span>12<span>]</span></a></sup><sup id="cite_ref-Loftus_12-2" class="reference"><a href="#cite_note-Loftus-12" title=""><span>[</span>13<span>]</span></a></sup></p>
<p>Warfarin administration in the second and third trimesters is much less commonly associated with birth defects, and when they do occur, are considerably different from fetal warfarin syndrome. The most common congenital abnormalities associated with warfarin use in late pregnancy are <a href="/wiki/Central_nervous_system" title="Central nervous system">central nervous system</a> disorders, including <a href="/wiki/Spasticity" title="Spasticity">spasticity</a> and <a href="/wiki/Seizure" title="Seizure">seizures</a>, and eye defects.<sup id="cite_ref-HDT_11-4" class="reference"><a href="#cite_note-HDT-11" title=""><span>[</span>12<span>]</span></a></sup><sup id="cite_ref-Loftus_12-3" class="reference"><a href="#cite_note-Loftus-12" title=""><span>[</span>13<span>]</span></a></sup></p>
<p>Anticoagulation therefore poses a problem in pregnant women requiring warfarin for vital indications, such as <a href="/wiki/Stroke" title="Stroke">stroke</a> prevention in those with <a href="/wiki/Artificial_heart_valve" title="Artificial heart valve">artificial heart valves</a>. Usually, warfarin is avoided in the first trimester, and a <a href="/wiki/Low_molecular_weight_heparin" title="Low molecular weight heparin">low molecular weight heparin</a> such as <a href="/wiki/Enoxaparin" title="Enoxaparin" class="mw-redirect">enoxaparin</a> is substituted; the risk of maternal hemorrhage with heparin use is high, and preterm birth and stillbirth may still occur, but heparins do not cross the placental barrier and therefore do not cause birth defects.<sup id="cite_ref-Loftus_12-4" class="reference"><a href="#cite_note-Loftus-12" title=""><span>[</span>13<span>]</span></a></sup> Various solutions exist for the time around delivery.</p>
<p><a name="Adverse_effects" id="Adverse_effects"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=5" title="Edit section: Adverse effects">edit</a>]</span> <span class="mw-headline">Adverse effects</span></h2>
<p><a name="Hemorrhage" id="Hemorrhage"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=6" title="Edit section: Hemorrhage">edit</a>]</span> <span class="mw-headline">Hemorrhage</span></h3>
<p>The only common <a href="/wiki/Adverse_drug_reaction" title="Adverse drug reaction">side effect</a> of warfarin is <a href="/wiki/Hemorrhage" title="Hemorrhage" class="mw-redirect">hemorrhage</a> (bleeding). The risk of severe bleeding is small but definite (a median annual rate of 0.9 to 2.7% has been reported<sup id="cite_ref-Horton_13-0" class="reference"><a href="#cite_note-Horton-13" title=""><span>[</span>14<span>]</span></a></sup>) and any benefit needs to outweigh this risk when warfarin is considered as a therapeutic measure. Risk of bleeding is augmented if the INR is out of range (due to accidental or deliberate overdose or due to interactions), and may cause <a href="/wiki/Hemoptysis" title="Hemoptysis">hemoptysis</a> (coughing up blood), excessive bruising, bleeding from nose or gums, or blood in <a href="/wiki/Urine" title="Urine">urine</a> or <a href="/wiki/Human_feces" title="Human feces">stool</a>.</p>
<p>The risks of bleeding is increased when warfarin is combined with <a href="/wiki/Antiplatelet_drug" title="Antiplatelet drug">antiplatelet drugs</a> such as <a href="/wiki/Clopidogrel" title="Clopidogrel">clopidogrel</a>, <a href="/wiki/Aspirin" title="Aspirin">aspirin</a>, or other <a href="/wiki/Nonsteroidal_anti-inflammatory_drug" title="Nonsteroidal anti-inflammatory drug" class="mw-redirect">nonsteroidal anti-inflammatory drugs</a>.<sup id="cite_ref-pmid17698822_14-0" class="reference"><a href="#cite_note-pmid17698822-14" title=""><span>[</span>15<span>]</span></a></sup> The risk may also be increased in elderly patients<sup id="cite_ref-pmid17515465_15-0" class="reference"><a href="#cite_note-pmid17515465-15" title=""><span>[</span>16<span>]</span></a></sup> and in patients on <a href="/wiki/Hemodialysis" title="Hemodialysis">hemodialysis</a>.<sup id="cite_ref-pmid17720522_16-0" class="reference"><a href="#cite_note-pmid17720522-16" title=""><span>[</span>17<span>]</span></a></sup></p>
<p><a name="Warfarin_necrosis" id="Warfarin_necrosis"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=7" title="Edit section: Warfarin necrosis">edit</a>]</span> <span class="mw-headline">Warfarin necrosis</span></h3>
<div class="rellink noprint relarticle mainarticle">Main article: <a href="/wiki/Warfarin_necrosis" title="Warfarin necrosis">warfarin necrosis</a></div>
<p>A rare but serious complication resulting from treatment with warfarin is <a href="/wiki/Warfarin_necrosis" title="Warfarin necrosis">warfarin necrosis</a>, which occurs more frequently shortly after commencing treatment in patients with a deficiency of <a href="/wiki/Protein_C" title="Protein C">protein C</a>. Protein C is an innate anticoagulant that, like the procoagulant factors that warfarin inhibits, requires vitamin K-dependent carboxylation for its activity. Since warfarin initially decreases protein C levels faster than the coagulation factors, it can paradoxically increase the blood's tendency to coagulate when treatment is first begun (many patients when starting on warfarin are given <a href="/wiki/Heparin" title="Heparin">heparin</a> in parallel to combat this), leading to massive thrombosis with skin <a href="/wiki/Necrosis" title="Necrosis">necrosis</a> and <a href="/wiki/Gangrene" title="Gangrene">gangrene</a> of limbs. Its natural counterpart, <a href="/wiki/Purpura_fulminans" title="Purpura fulminans">purpura fulminans</a>, occurs in children who are <a href="/wiki/Homozygous" title="Homozygous" class="mw-redirect">homozygous</a> for certain protein C mutations.<sup id="cite_ref-pmid10718793_17-0" class="reference"><a href="#cite_note-pmid10718793-17" title=""><span>[</span>18<span>]</span></a></sup></p>
<p><a name="Osteoporosis" id="Osteoporosis"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=8" title="Edit section: Osteoporosis">edit</a>]</span> <span class="mw-headline">Osteoporosis</span></h3>
<p>After initial reports that warfarin could reduce <a href="/wiki/Bone_mineral_density" title="Bone mineral density" class="mw-redirect">bone mineral density</a>, several studies have demonstrated a link between warfarin use and <a href="/wiki/Osteoporosis" title="Osteoporosis">osteoporosis</a>-related <a href="/wiki/Bone_fracture" title="Bone fracture">fracture</a>. A 1999 study in 572 women taking warfarin for deep venous thrombosis, risk of vertebral fracture and rib fracture was increased; other fracture types did not occur more commonly.<sup id="cite_ref-18" class="reference"><a href="#cite_note-18" title=""><span>[</span>19<span>]</span></a></sup> A 2002 study looking at a randomly selected selection of 1523 patients with osteoporotic fracture found no increased exposure to anticoagulants compared to controls, and neither did stratification of the duration of anticoagulation reveal a trend towards fracture.<sup id="cite_ref-19" class="reference"><a href="#cite_note-19" title=""><span>[</span>20<span>]</span></a></sup></p>
<p>A 2006 retrospective study of 14,564 Medicare recipients showed that warfarin use for more than one year was linked with a 60% increased risk of osteoporosis-related fracture in men; there was no association in women. The mechanism was thought to be either reduced intake of vitamin K, which is necessary for bone health, or interaction by warfarin with carboxylation of certain bone proteins.<sup id="cite_ref-20" class="reference"><a href="#cite_note-20" title=""><span>[</span>21<span>]</span></a></sup></p>
<p><a name="Purple_toe_syndrome" id="Purple_toe_syndrome"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=9" title="Edit section: Purple toe syndrome">edit</a>]</span> <span class="mw-headline">Purple toe syndrome</span></h3>
<p>Another rare complication that may occur early during warfarin treatment (usually within 3 to 8 weeks) is <i><a href="/wiki/Cholesterol_embolism" title="Cholesterol embolism">purple toe syndrome</a></i>. This condition is thought to result from small deposits of <a href="/wiki/Cholesterol" title="Cholesterol">cholesterol</a> breaking loose and flowing into the blood vessels in the skin of the feet, which causes a blueish purple color and may be painful. It is typically thought to affect the big toe, but it affects other parts of the feet as well, including the bottom of the foot (plantar surface). The occurrence of purple toe syndrome may require discontinuation of warfarin.<sup id="cite_ref-21" class="reference"><a href="#cite_note-21" title=""><span>[</span>22<span>]</span></a></sup></p>
<p><a name="Pharmacology" id="Pharmacology"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=10" title="Edit section: Pharmacology">edit</a>]</span> <span class="mw-headline">Pharmacology</span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:182px;"><a href="/wiki/File:Warfarintablets5-3-1.jpg" class="image" title="3&#160;mg (blue), 5&#160;mg (pink) and 1&#160;mg (brown) warfarin tablets (UK colours)"><img alt="" src="http://upload.wikimedia.org/wikipedia/en/thumb/5/59/Warfarintablets5-3-1.jpg/180px-Warfarintablets5-3-1.jpg" width="180" height="112" border="0" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Warfarintablets5-3-1.jpg" class="internal" title="Enlarge"><img src="/skins-1.5/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
3&#160;mg (blue), 5&#160;mg (pink) and 1&#160;mg (brown) warfarin tablets (UK colours)</div>
</div>
</div>
<p><a name="Pharmacokinetics" id="Pharmacokinetics"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=11" title="Edit section: Pharmacokinetics">edit</a>]</span> <span class="mw-headline">Pharmacokinetics</span></h3>
<p>Warfarin consists of a racemic mixture of two active optical <a href="/wiki/Isomer" title="Isomer">isomers</a>—<i>R</i>- and <i>S</i>- forms—each of which is cleared by different pathways. S-warfarin has five times the potency of the R-isomer with respect to vitamin K antagonism.<sup id="cite_ref-Hirsh_8-2" class="reference"><a href="#cite_note-Hirsh-8" title=""><span>[</span>9<span>]</span></a></sup></p>
<p>Warfarin is slower-acting than the common anticoagulant <a href="/wiki/Heparin" title="Heparin">heparin</a>, though it has a number of advantages. Heparin must be given by injection, whereas warfarin is available orally. Warfarin has a long half-life and need only be given once a day. Heparin can also cause a prothrombotic condition, <a href="/wiki/Heparin-induced_thrombocytopenia" title="Heparin-induced thrombocytopenia">heparin-induced thrombocytopenia</a> (an antibody-mediated decrease in <a href="/wiki/Platelet" title="Platelet">platelet</a> levels), which increases the risk for <a href="/wiki/Thrombosis" title="Thrombosis">thrombosis</a>. Warfarin's long half life, on the other hand, means it often takes several days to reach therapeutic effect. Furthermore, if given initially without additional anticoagulant cover, it can increase thrombosis risk. For these main reasons, <a href="/wiki/Hospital" title="Hospital">hospitalised</a> patients are usually given heparin first, and are then moved on to warfarin.</p>
<p><a name="Mechanism_of_action" id="Mechanism_of_action"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=12" title="Edit section: Mechanism of action">edit</a>]</span> <span class="mw-headline">Mechanism of action</span></h3>
<p>Warfarin inhibits the <a href="/wiki/Vitamin_K" title="Vitamin K">vitamin K</a>-dependent synthesis of biologically active forms of the <a href="/wiki/Calcium" title="Calcium">calcium</a>-dependent <a href="/wiki/Clotting" title="Clotting" class="mw-redirect">clotting</a> factors <a href="/wiki/Thrombin" title="Thrombin">II</a>, <a href="/wiki/Factor_VII" title="Factor VII">VII</a>, <a href="/wiki/Factor_IX" title="Factor IX">IX</a> and <a href="/wiki/Factor_X" title="Factor X">X</a>, as well as the regulatory factors <a href="/wiki/Protein_C" title="Protein C">protein C</a>, <a href="/wiki/Protein_S" title="Protein S">protein S</a>, and <a href="/wiki/Protein_Z" title="Protein Z">protein Z</a>. Other proteins not involved in blood clotting, such as <a href="/wiki/Osteocalcin" title="Osteocalcin">osteocalcin</a>, or <a href="/wiki/Matrix_gla_protein" title="Matrix gla protein">matrix Gla protein</a>, may also be affected.</p>
<p>The precursors of these factors require <a href="/wiki/Carboxylation" title="Carboxylation">carboxylation</a> of their <a href="/wiki/Glutamic_acid" title="Glutamic acid">glutamic acid</a> residues to allow the coagulation factors to bind to <a href="/wiki/Phospholipid" title="Phospholipid">phospholipid</a> surfaces inside blood vessels, on the vascular <a href="/wiki/Endothelium" title="Endothelium">endothelium</a>. The enzyme that carries out the carboxylation of glutamic acid is <a href="/wiki/Gamma-glutamyl_carboxylase" title="Gamma-glutamyl carboxylase">gamma-glutamyl carboxylase</a>. The carboxylation reaction will proceed only if the carboxylase enzyme is able to convert a <a href="/wiki/Reduction_(chemistry)" title="Reduction (chemistry)" class="mw-redirect">reduced</a> form of vitamin K (vitamin K hydroquinone) to vitamin K epoxide at the same time. The vitamin K epoxide is in turn recycled back to vitamin K and vitamin K hydroquinone by another enzyme, the <a href="/wiki/Vitamin_K_epoxide_reductase" title="Vitamin K epoxide reductase">vitamin K epoxide reductase</a> (VKOR). Warfarin inhibits epoxide reductase<sup id="cite_ref-Whitlon_6-1" class="reference"><a href="#cite_note-Whitlon-6" title=""><span>[</span>7<span>]</span></a></sup> (specifically the VKORC1 subunit<sup id="cite_ref-22" class="reference"><a href="#cite_note-22" title=""><span>[</span>23<span>]</span></a></sup><sup id="cite_ref-pmid14765194_23-0" class="reference"><a href="#cite_note-pmid14765194-23" title=""><span>[</span>24<span>]</span></a></sup>), thereby diminishing available vitamin K and vitamin K hydroquinone in the tissues, which inhibits the carboxylation activity of the glutamyl carboxylase. When this occurs, the coagulation factors are no longer carboxylated at certain <a href="/wiki/Glutamic_acid" title="Glutamic acid">glutamic acid</a> residues, and are incapable of binding to the <a href="/wiki/Endothelial" title="Endothelial" class="mw-redirect">endothelial</a> surface of blood vessels, and are thus biologically inactive. As the body's stores of previously-produced active factors degrade (over several days) and are replaced by inactive factors, the anticoagulation effect becomes apparent. The coagulation factors are produced, but have decreased functionality due to undercarboxylation; they are collectively referred to as PIVKAs (proteins induced [by] vitamin K absence/antagonism), and individual coagulation factors as PIVKA-<i>number</i> (e.g. <a href="/wiki/Des-gamma_carboxyprothrombin" title="Des-gamma carboxyprothrombin">PIVKA-II</a>). The end result of warfarin use, therefore, is to diminish blood clotting in the patient.</p>
<p>The initial effect of warfarin administration is to briefly <i>promote</i> clot formation. This is because the level of <a href="/wiki/Protein_S" title="Protein S">protein S</a> is also dependent on vitamin K activity. Reduced levels of protein S lead to a reduction in activity of protein C (for which it is the co-factor) and therefore reduced degradation of <a href="/wiki/Factor_V" title="Factor V">factor Va</a> and <a href="/wiki/Factor_VIII" title="Factor VIII">factor VIIIa</a>. This then causes the hemostasis system to be temporarily biased towards thrombus formation, leading to a prothrombotic state. This is one of the benefits of co-administering <a href="/wiki/Heparin" title="Heparin">heparin</a>, an anticoagulant that acts upon <a href="/wiki/Antithrombin" title="Antithrombin">antithrombin</a> and helps reduce the risk of thrombosis, which is common practice in settings where warfarin is loaded rapidly.</p>
<p><a name="Antagonism" id="Antagonism"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=13" title="Edit section: Antagonism">edit</a>]</span> <span class="mw-headline">Antagonism</span></h3>
<p>The effects of warfarin can be reversed with vitamin K, or, when rapid reversal is needed (such as in case of severe bleeding), with <a href="/wiki/Prothrombin_complex_concentrate" title="Prothrombin complex concentrate">prothrombin complex concentrate</a>—which contains only the factors inhibited by warfarin—or <a href="/wiki/Fresh_frozen_plasma" title="Fresh frozen plasma" class="mw-redirect">fresh frozen plasma</a> (depending upon the clinical indication) in addition to <a href="/wiki/Intravenous_therapy" title="Intravenous therapy">intravenous</a> vitamin K.</p>
<p>Details on reversing warfarin are provided in <a href="/wiki/Clinical_practice_guidelines" title="Clinical practice guidelines" class="mw-redirect">clinical practice guidelines</a> from the <a href="/wiki/American_College_of_Chest_Physicians" title="American College of Chest Physicians">American College of Chest Physicians</a>.<sup id="cite_ref-pmid15383473_24-0" class="reference"><a href="#cite_note-pmid15383473-24" title=""><span>[</span>25<span>]</span></a></sup> For patients with an <a href="/wiki/International_normalized_ratio" title="International normalized ratio" class="mw-redirect">international normalized ratio</a> (INR) between 4.5 and 10.0, a small dose of oral vitamin K is sufficient.<sup id="cite_ref-pmid12186515_25-0" class="reference"><a href="#cite_note-pmid12186515-25" title=""><span>[</span>26<span>]</span></a></sup></p>
<p><a name="Pharmacogenomics" id="Pharmacogenomics"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=14" title="Edit section: Pharmacogenomics">edit</a>]</span> <span class="mw-headline">Pharmacogenomics</span></h3>
<p>Warfarin activity is determined partially by genetic factors. The American <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration" class="mw-redirect">Food and Drug Administration</a> "highlights the opportunity for healthcare providers to use genetic tests to improve their initial estimate of what is a reasonable warfarin dose for individual patients".<sup id="cite_ref-26" class="reference"><a href="#cite_note-26" title=""><span>[</span>27<span>]</span></a></sup> <a href="/wiki/Polymorphism_(biology)" title="Polymorphism (biology)">Polymorphisms</a> in two genes are particularly important.</p>
<p><a name="VKORC1" id="VKORC1"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=15" title="Edit section: VKORC1">edit</a>]</span> <span class="mw-headline">VKORC1</span></h4>
<p><a href="/wiki/VKORC1" title="VKORC1">VKORC1</a> polymorphisms explain 30% of the dose variation between patients:<sup id="cite_ref-pmid15883587_27-0" class="reference"><a href="#cite_note-pmid15883587-27" title=""><span>[</span>28<span>]</span></a></sup> particular mutations make VKORC1 less susceptible to suppression by warfarin.<sup id="cite_ref-pmid14765194_23-1" class="reference"><a href="#cite_note-pmid14765194-23" title=""><span>[</span>24<span>]</span></a></sup> There are two main haplotypes that explain 25% of variation: low-dose haplotype group (A) and a high-dose haplotype group (B).<sup id="cite_ref-pmid15930419_28-0" class="reference"><a href="#cite_note-pmid15930419-28" title=""><span>[</span>29<span>]</span></a></sup> <i>VKORC1</i> polymorphisms explain why <a href="/wiki/African_American" title="African American">African Americans</a> are on average relatively resistant to warfarin (higher proportion of group B haplotypes), while <a href="/wiki/Asian_American" title="Asian American">Asian Americans</a> are generally more sensitive (higher proportion of group A haplotypes).<sup id="cite_ref-pmid15930419_28-1" class="reference"><a href="#cite_note-pmid15930419-28" title=""><span>[</span>29<span>]</span></a></sup> Group A <i>VKORC1</i> polymorphisms lead to a more rapid achievement of a therapeutic INR, but also a shorter time to reach an INR over 4, which is associated with bleeding.<sup id="cite_ref-pmid18322281_29-0" class="reference"><a href="#cite_note-pmid18322281-29" title=""><span>[</span>30<span>]</span></a></sup></p>
<p><a name="CYP2C9" id="CYP2C9"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=16" title="Edit section: CYP2C9">edit</a>]</span> <span class="mw-headline">CYP2C9</span></h4>
<p><i><a href="/wiki/CYP2C9" title="CYP2C9">CYP2C9</a></i> polymorphisms explain 10% of the dose variation between patients, <sup id="cite_ref-pmid15883587_27-1" class="reference"><a href="#cite_note-pmid15883587-27" title=""><span>[</span>28<span>]</span></a></sup> mainly among Caucasian patients as these variants are rare in African American and most Asian populations.<sup id="cite_ref-pmid15714076_30-0" class="reference"><a href="#cite_note-pmid15714076-30" title=""><span>[</span>31<span>]</span></a></sup> These <i>CYP2C9</i> polymorphisms do not influence time to effective INR as opposed to <i>VKORC1</i>, but does shorten the time to INR &gt;4.<sup id="cite_ref-pmid18322281_29-1" class="reference"><a href="#cite_note-pmid18322281-29" title=""><span>[</span>30<span>]</span></a></sup></p>
<p><a name="Loading_regimens" id="Loading_regimens"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=17" title="Edit section: Loading regimens">edit</a>]</span> <span class="mw-headline">Loading regimens</span></h3>
<p>Because of warfarin's poorly-predictable <a href="/wiki/Pharmacokinetics" title="Pharmacokinetics">pharmacokinetics</a>, several researchers have proposed algorithms for commencing warfarin treatment:</p>
<ul>
<li>The Kovacs 10 mg algorithm was better than a 5 mg algorithm.<sup id="cite_ref-pmid12729425_31-0" class="reference"><a href="#cite_note-pmid12729425-31" title=""><span>[</span>32<span>]</span></a></sup></li>
<li>The Fennerty 10 mg regimen is for urgent anticoagulation<sup id="cite_ref-pmid3144365_32-0" class="reference"><a href="#cite_note-pmid3144365-32" title=""><span>[</span>33<span>]</span></a></sup></li>
<li>The Tait 5 mg regimen is for "routine" (low-risk) anticoagulation<sup id="cite_ref-pmid9633885_33-0" class="reference"><a href="#cite_note-pmid9633885-33" title=""><span>[</span>34<span>]</span></a></sup></li>
<li>From a cohort of orthopedic patients, Millican <i>et al.</i> derived an 8-value model, including <i>CYP29C</i> and <i>VKORC1</i> genotype results, that could predict 80% of the variation in warfarin doses. It is awaiting validation in larger populations and has not been reproduced in those who require warfarin for other indications.<sup id="cite_ref-34" class="reference"><a href="#cite_note-34" title=""><span>[</span>35<span>]</span></a></sup></li>
<li>Lenzini <i>et al.</i> derived and prospectively validated a model including <i>CYP29C</i> and <i>VKORC1</i> genotypes. This model could predict 70% of the variation in warfarin doses in a validation cohort (versus 48% without genotype). The pharmacogenetic protocol lead to a significant reduction in out of range INR values.<sup id="cite_ref-35" class="reference"><a href="#cite_note-35" title=""><span>[</span>36<span>]</span></a></sup></li>
<li>www.WarfarinDosing.org, is a non-profit website programmed with dosing calculators and other decision support tools for clinicians' use when initiating warfarin therapy.<sup id="cite_ref-36" class="reference"><a href="#cite_note-36" title=""><span>[</span>37<span>]</span></a></sup></li>
</ul>
<p><a name="Adjusting_the_maintenance_dose" id="Adjusting_the_maintenance_dose"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=18" title="Edit section: Adjusting the maintenance dose">edit</a>]</span> <span class="mw-headline">Adjusting the maintenance dose</span></h3>
<p>Recommendations by many national bodies including the <a href="/wiki/American_College_of_Chest_Physicians" title="American College of Chest Physicians">American College of Chest Physicians</a><sup id="cite_ref-pmid15383473_24-1" class="reference"><a href="#cite_note-pmid15383473-24" title=""><span>[</span>25<span>]</span></a></sup> have been distilled to help manage dose adjustments.<sup id="cite_ref-37" class="reference"><a href="#cite_note-37" title=""><span>[</span>38<span>]</span></a></sup></p>
<p><a name="Self-testing_and_home_monitoring" id="Self-testing_and_home_monitoring"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=19" title="Edit section: Self-testing and home monitoring">edit</a>]</span> <span class="mw-headline">Self-testing and home monitoring</span></h3>
<p>Patients are making increasing use of self-testing and home monitoring of oral anticoagulation. International guidelines were published in 2005 to govern home testing, by the International Self-Monitoring Association for Oral Anticoagulation.<sup id="cite_ref-Ansell_2005_38-0" class="reference"><a href="#cite_note-Ansell_2005-38" title=""><span>[</span>39<span>]</span></a></sup></p>
<p>The international guidelines study stated: "The consensus agrees that patient self-testing and patient self-management are effective methods of monitoring oral anticoagulation therapy, providing outcomes at least as good as, and possibly better than, those achieved with an anticoagulation clinic. All patients must be appropriately selected and trained. Currently-available self-testing/self-management devices give INR results that are comparable with those obtained in laboratory testing."<sup id="cite_ref-Ansell_1-2" class="reference"><a href="#cite_note-Ansell-1" title=""><span>[</span>2<span>]</span></a></sup></p>
<p><a name="Drug_interactions" id="Drug_interactions"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=20" title="Edit section: Drug interactions">edit</a>]</span> <span class="mw-headline">Drug interactions</span></h2>
<p>Warfarin <a href="/wiki/Drug_interaction" title="Drug interaction">interacts</a> with many commonly-used drugs, and the <a href="/wiki/Drug_metabolism" title="Drug metabolism">metabolism</a> of warfarin varies greatly between patients. Some foods have also been reported to interact with warfarin.<sup id="cite_ref-Holbrook_0-2" class="reference"><a href="#cite_note-Holbrook-0" title=""><span>[</span>1<span>]</span></a></sup> Apart from the metabolic interactions, highly protein bound drugs can displace warfarin from <a href="/wiki/Serum_albumin" title="Serum albumin">serum albumin</a> and cause an increase in the INR.<sup id="cite_ref-39" class="reference"><a href="#cite_note-39" title=""><span>[</span>40<span>]</span></a></sup> This makes finding the correct dosage difficult, and accentuates the need of monitoring; when initiating a medication that is known to interact with warfarin (e.g. <a href="/wiki/Simvastatin" title="Simvastatin">simvastatin</a>), <a href="/wiki/International_normalized_ratio" title="International normalized ratio" class="mw-redirect">INR</a> checks are increased or dosages adjusted until a new ideal dosage is found.</p>
<p>Many commonly-used antibiotics, such as <a href="/wiki/Metronidazole" title="Metronidazole">metronidazole</a> or the <a href="/wiki/Macrolide" title="Macrolide">macrolides</a>, will greatly increase the effect of warfarin by reducing the <a href="/wiki/Drug_metabolism" title="Drug metabolism">metabolism</a> of warfarin in the body. Other <a href="/wiki/Broad-spectrum_antibiotic" title="Broad-spectrum antibiotic">broad-spectrum antibiotics</a> can reduce the amount of the normal <a href="/wiki/Gut_flora" title="Gut flora">bacterial flora in the bowel</a>, which make significant quantities of vitamin K, thus potentiating the effect of warfarin.<sup id="cite_ref-Juurlink_40-0" class="reference"><a href="#cite_note-Juurlink-40" title=""><span>[</span>41<span>]</span></a></sup> In addition, food that contains large quantities of vitamin K will reduce the warfarin effect.<sup id="cite_ref-Holbrook_0-3" class="reference"><a href="#cite_note-Holbrook-0" title=""><span>[</span>1<span>]</span></a></sup> <a href="/wiki/Thyroid" title="Thyroid">Thyroid</a> activity also appears to influence warfarin dosing requirements;<sup id="cite_ref-Kurnik_41-0" class="reference"><a href="#cite_note-Kurnik-41" title=""><span>[</span>42<span>]</span></a></sup> <a href="/wiki/Hypothyroidism" title="Hypothyroidism">hypothyroidism</a> (decreased thyroid function) makes people less responsive to warfarin treatment,<sup id="cite_ref-42" class="reference"><a href="#cite_note-42" title=""><span>[</span>43<span>]</span></a></sup> while <a href="/wiki/Hyperthyroidism" title="Hyperthyroidism">hyperthyroidism</a> (overactive thyroid) boosts the anticoagulant effect.<sup id="cite_ref-43" class="reference"><a href="#cite_note-43" title=""><span>[</span>44<span>]</span></a></sup> Several mechanisms have been proposed for this effect, including changes in the rate of breakdown of clotting factors and changes in the metabolism of warfarin.<sup id="cite_ref-44" class="reference"><a href="#cite_note-44" title=""><span>[</span>45<span>]</span></a></sup><sup id="cite_ref-Kurnik_41-1" class="reference"><a href="#cite_note-Kurnik-41" title=""><span>[</span>42<span>]</span></a></sup></p>
<p>Excessive use of alcohol is also known to affect the metabolism of warfarin and can elevate the INR.<sup id="cite_ref-45" class="reference"><a href="#cite_note-45" title=""><span>[</span>46<span>]</span></a></sup> Patients are often cautioned against the excessive use of alcohol while taking warfarin.</p>
<p>Warfarin also interacts with many herbs,<sup id="cite_ref-drug-herb_46-0" class="reference"><a href="#cite_note-drug-herb-46" title=""><span>[</span>47<span>]</span></a></sup> some are used in food such as <a href="/wiki/Ginger" title="Ginger">Ginger</a> taken for nausea and poor digestion and <a href="/wiki/Garlic" title="Garlic">Garlic</a>, used to help lower high <a href="/wiki/Cholesterol" title="Cholesterol">cholesterol</a> levels, high <a href="/wiki/Triglycerides" title="Triglycerides" class="mw-redirect">triglycerides</a>, and high <a href="/wiki/Blood_pressure" title="Blood pressure">blood pressure</a>, when used as a supplement, not in the diet,<sup class="noprint Template-Fact"><span title="This claim needs references to reliable sources&#160;since January 2009" style="white-space: nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed">citation needed</a></i>]</span></sup> or for medicinal purposes such as <a href="/wiki/Ginseng" title="Ginseng">Ginseng</a>, taken to help with fatigue and weakness, and <a href="/wiki/Ginkgo" title="Ginkgo">Ginkgo</a> (a.k.a. Ginkgo Biloba), used to increase brain blood flow, prevent dementia, and improve memory, may all increase bleeding and brusing in people taking warfarin, similar effects have been reported with <a href="/wiki/Borage_oil" title="Borage oil" class="mw-redirect">borage</a> (<a href="/wiki/Starflower" title="Starflower">starflower</a>) oil or fish oils.<sup id="cite_ref-47" class="reference"><a href="#cite_note-47" title=""><span>[</span>48<span>]</span></a></sup> <a href="/wiki/St._John%27s_Wort" title="St. John's Wort" class="mw-redirect">St. John's Wort</a>, sometimes recommended to help with mild to moderate depression, interacts with warfarin causing a reduced anticoagulant effect, with potential for <a href="/wiki/Transplant_rejection" title="Transplant rejection">transplant rejection</a> and <a href="/wiki/Arrhythmia" title="Arrhythmia" class="mw-redirect">arrhythmia</a> or loss of <a href="/wiki/Asthma" title="Asthma">asthma</a> control and seizures.<sup id="cite_ref-48" class="reference"><a href="#cite_note-48" title=""><span>[</span>49<span>]</span></a></sup></p>
<p>Between 2003 and 2004, the UK <a href="/wiki/Committee_on_Safety_of_Medicines" title="Committee on Safety of Medicines">Committee on Safety of Medicines</a> received several reports of increased INR and risk of hemorrhage in people taking warfarin and <a href="/wiki/Cranberry" title="Cranberry">cranberry juice</a>.<sup id="cite_ref-49" class="reference"><a href="#cite_note-49" title=""><span>[</span>50<span>]</span></a></sup><sup id="cite_ref-Suvarna_50-0" class="reference"><a href="#cite_note-Suvarna-50" title=""><span>[</span>51<span>]</span></a></sup><sup id="cite_ref-Aston_51-0" class="reference"><a href="#cite_note-Aston-51" title=""><span>[</span>52<span>]</span></a></sup> Data establishing a causal relationship is still lacking, and a 2006 review found no cases of this interaction reported to the FDA;<sup id="cite_ref-Aston_51-1" class="reference"><a href="#cite_note-Aston-51" title=""><span>[</span>52<span>]</span></a></sup> nevertheless, several authors have recommended that both doctors and patients be made aware of its possibility.<sup id="cite_ref-Pham_52-0" class="reference"><a href="#cite_note-Pham-52" title=""><span>[</span>53<span>]</span></a></sup> The mechanism behind the interaction is still unclear.<sup id="cite_ref-Aston_51-2" class="reference"><a href="#cite_note-Aston-51" title=""><span>[</span>52<span>]</span></a></sup></p>
<p><a name="Use_as_a_pesticide" id="Use_as_a_pesticide"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=21" title="Edit section: Use as a pesticide">edit</a>]</span> <span class="mw-headline">Use as a pesticide</span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:182px;"><a href="/wiki/File:Rattenvergifwaarschuwing_edit.JPG" class="image" title="Warning label on a tube of rat poison laid on a dike of the Scheldt river in Steendorp, Belgium. The tube contains bromadiolone, a second-generation (&quot;super-warfarin&quot;) anticoagulant."><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/c/cb/Rattenvergifwaarschuwing_edit.JPG/180px-Rattenvergifwaarschuwing_edit.JPG" width="180" height="135" border="0" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Rattenvergifwaarschuwing_edit.JPG" class="internal" title="Enlarge"><img src="/skins-1.5/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Warning label on a tube of rat poison laid on a dike of the <a href="/wiki/Scheldt" title="Scheldt">Scheldt</a> river in Steendorp, Belgium. The tube contains <a href="/wiki/Bromadiolone" title="Bromadiolone" class="mw-redirect">bromadiolone</a>, a second-generation ("super-warfarin") anticoagulant.</div>
</div>
</div>
<p>To this day, coumarins are used as <a href="/wiki/Rodenticide" title="Rodenticide">rodenticides</a> for controlling <a href="/wiki/Rat" title="Rat">rats</a> and <a href="/wiki/Mouse" title="Mouse">mice</a> in residential, industrial, and agricultural areas. Warfarin is both odorless and tasteless, and is effective when mixed with food <a href="/wiki/Bait_(luring_substance)" title="Bait (luring substance)">bait</a>, because the <a href="/wiki/Rodent" title="Rodent">rodents</a> will return to the bait and continue to feed over a period of days until a lethal dose is accumulated (considered to be 1&#160;mg/kg/day over about six days). It may also be mixed with <a href="/wiki/Talc" title="Talc">talc</a> and used as a <i>tracking powder</i>, which accumulates on the animal's skin and fur, and is subsequently consumed during grooming. The <a href="/wiki/LD50" title="LD50" class="mw-redirect">LD<sub>50</sub></a> is 50–500&#160;mg/kg. The <a href="/wiki/IDLH" title="IDLH">IDLH</a> value is 100&#160;mg/m³ (warfarin; various species).<sup id="cite_ref-53" class="reference"><a href="#cite_note-53" title=""><span>[</span>54<span>]</span></a></sup></p>
<p>The use of warfarin as a rat poison is now declining because many rat populations have developed resistance to it, and poisons of considerably greater potency are now available. Other coumarins used as rodenticides include <a href="/wiki/Coumatetralyl" title="Coumatetralyl">coumatetralyl</a> and <a href="/wiki/Brodifacoum" title="Brodifacoum">brodifacoum</a>, which is sometimes referred to as "super-warfarin", because it is more potent, longer-acting, and effective even in rat and mouse populations that are resistant to warfarin. Unlike warfarin, which is readily excreted, newer anticoagulant poisons also <a href="/wiki/Bioaccumulation" title="Bioaccumulation">accumulate</a> in the liver and kidneys after ingestion.<sup id="cite_ref-NZToxins_54-0" class="reference"><a href="#cite_note-NZToxins-54" title=""><span>[</span>55<span>]</span></a></sup></p>
<p><a name="References" id="References"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=22" title="Edit section: References">edit</a>]</span> <span class="mw-headline">References</span></h2>
<div class="references-small references-column-count references-column-count-2" style="-moz-column-count:2; column-count:2;">
<ol class="references">
<li id="cite_note-Holbrook-0">^ <a href="#cite_ref-Holbrook_0-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Holbrook_0-1" title=""><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Holbrook_0-2" title=""><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Holbrook_0-3" title=""><sup><i><b>d</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFHolbrook_AM.2C_Pereira_JA.2C_Labiris_R.2C_.27.27et_al.27.272005">Holbrook AM, Pereira JA, Labiris R, <i>et al</i> (2005). "<a href="http://archinte.ama-assn.org/cgi/content/full/165/10/1095" class="external text" title="http://archinte.ama-assn.org/cgi/content/full/165/10/1095" rel="nofollow">Systematic overview of warfarin and its drug and food interactions</a>". <i>Arch. Intern. Med.</i> <b>165</b> (10): 1095–106. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1001%2Farchinte.165.10.1095" class="external text" title="http://dx.doi.org/10.1001%2Farchinte.165.10.1095" rel="nofollow">10.1001/archinte.165.10.1095</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15911722" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15911722">PMID 15911722</a><span class="printonly">. <a href="http://archinte.ama-assn.org/cgi/content/full/165/10/1095" class="external free" title="http://archinte.ama-assn.org/cgi/content/full/165/10/1095" rel="nofollow">http://archinte.ama-assn.org/cgi/content/full/165/10/1095</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Systematic+overview+of+warfarin+and+its+drug+and+food+interactions&amp;rft.jtitle=Arch.+Intern.+Med.&amp;rft.aulast=Holbrook+AM%2C+Pereira+JA%2C+Labiris+R%2C+%27%27et+al%27%27&amp;rft.au=Holbrook+AM%2C+Pereira+JA%2C+Labiris+R%2C+%27%27et+al%27%27&amp;rft.date=2005&amp;rft.volume=165&amp;rft.issue=10&amp;rft.pages=1095%E2%80%93106&amp;rft_id=info:doi/10.1001%2Farchinte.165.10.1095&amp;rft_id=info:pmid/15911722&amp;rft_id=http%3A%2F%2Farchinte.ama-assn.org%2Fcgi%2Fcontent%2Ffull%2F165%2F10%2F1095&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Ansell-1">^ <a href="#cite_ref-Ansell_1-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Ansell_1-1" title=""><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Ansell_1-2" title=""><sup><i><b>c</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFAnsell_J.2C_Hirsh_J.2C_Poller_L.2C_Bussey_H.2C_Jacobson_A.2C_Hylek_E2004">Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E (2004). "<a href="http://www.chestjournal.org/cgi/content/full/126/3_suppl/204S" class="external text" title="http://www.chestjournal.org/cgi/content/full/126/3_suppl/204S" rel="nofollow">The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy</a>". <i>Chest</i> <b>126</b> (3 Suppl): 204S–233S. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1378%2Fchest.126.3_suppl.204S" class="external text" title="http://dx.doi.org/10.1378%2Fchest.126.3_suppl.204S" rel="nofollow">10.1378/chest.126.3_suppl.204S</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15383473" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15383473">PMID 15383473</a><span class="printonly">. <a href="http://www.chestjournal.org/cgi/content/full/126/3_suppl/204S" class="external free" title="http://www.chestjournal.org/cgi/content/full/126/3_suppl/204S" rel="nofollow">http://www.chestjournal.org/cgi/content/full/126/3_suppl/204S</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The+pharmacology+and+management+of+the+vitamin+K+antagonists%3A+the+Seventh+ACCP+Conference+on+Antithrombotic+and+Thrombolytic+Therapy&amp;rft.jtitle=Chest&amp;rft.aulast=Ansell+J%2C+Hirsh+J%2C+Poller+L%2C+Bussey+H%2C+Jacobson+A%2C+Hylek+E&amp;rft.au=Ansell+J%2C+Hirsh+J%2C+Poller+L%2C+Bussey+H%2C+Jacobson+A%2C+Hylek+E&amp;rft.date=2004&amp;rft.volume=126&amp;rft.issue=3+Suppl&amp;rft.pages=204S%E2%80%93233S&amp;rft_id=info:doi/10.1378%2Fchest.126.3_suppl.204S&amp;rft_id=info:pmid/15383473&amp;rft_id=http%3A%2F%2Fwww.chestjournal.org%2Fcgi%2Fcontent%2Ffull%2F126%2F3_suppl%2F204S&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-2"><b><a href="#cite_ref-2" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFSchofield_FW1924">Schofield FW (1924). "Damaged sweet clover; the cause of a new disease in cattle simulating haemorrhagic septicemia and blackleg". <i>J Am Vet Med Ass</i> <b>64</b>: 553–6.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Damaged+sweet+clover%3B+the+cause+of+a+new+disease+in+cattle+simulating+haemorrhagic+septicemia+and+blackleg&amp;rft.jtitle=J+Am+Vet+Med+Ass&amp;rft.aulast=Schofield+FW&amp;rft.au=Schofield+FW&amp;rft.date=1924&amp;rft.volume=64&amp;rft.pages=553%E2%80%936&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-3"><b><a href="#cite_ref-3" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFRoderick_LM1931">Roderick LM (1931). "A problem in the coagulation of the blood; "sweet clover disease of the cattle"". <i>Am J Physiol</i> <b>96</b>: 413–6.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=A+problem+in+the+coagulation+of+the+blood%3B+%22sweet+clover+disease+of+the+cattle%22&amp;rft.jtitle=Am+J+Physiol&amp;rft.aulast=Roderick+LM&amp;rft.au=Roderick+LM&amp;rft.date=1931&amp;rft.volume=96&amp;rft.pages=413%E2%80%936&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span> <a href="http://ajplegacy.physiology.org/cgi/reprint/96/2/413" class="external text" title="http://ajplegacy.physiology.org/cgi/reprint/96/2/413" rel="nofollow">PDF (subscriber only)</a>.</li>
<li id="cite_note-4"><b><a href="#cite_ref-4" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFStahmann_MA.2C_Huebner_CF.2C_Link_KP1941">Stahmann MA, Huebner CF, Link KP (04/01/1941). "<a href="http://www.jbc.org/cgi/reprint/138/2/513" class="external text" title="http://www.jbc.org/cgi/reprint/138/2/513" rel="nofollow">Studies on the hemorrhagic sweet clover disease. V. Identification and synthesis of the hemorrhagic agent</a>". <i>J Biol Chem</i> <b>138</b> (2): 513–27<span class="printonly">. <a href="http://www.jbc.org/cgi/reprint/138/2/513" class="external free" title="http://www.jbc.org/cgi/reprint/138/2/513" rel="nofollow">http://www.jbc.org/cgi/reprint/138/2/513</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Studies+on+the+hemorrhagic+sweet+clover+disease.+V.+Identification+and+synthesis+of+the+hemorrhagic+agent&amp;rft.jtitle=J+Biol+Chem&amp;rft.aulast=Stahmann+MA%2C+Huebner+CF%2C+Link+KP&amp;rft.au=Stahmann+MA%2C+Huebner+CF%2C+Link+KP&amp;rft.date=04%2F01%2F1941&amp;rft.volume=138&amp;rft.issue=2&amp;rft.pages=513%E2%80%9327&amp;rft_id=http%3A%2F%2Fwww.jbc.org%2Fcgi%2Freprint%2F138%2F2%2F513&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid13619027-5">^ <a href="#cite_ref-pmid13619027_5-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid13619027_5-1" title=""><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid13619027_5-2" title=""><sup><i><b>c</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFLink_KP1959">Link KP (01/01/1959). "<a href="http://circ.ahajournals.org/cgi/reprint/19/1/97" class="external text" title="http://circ.ahajournals.org/cgi/reprint/19/1/97" rel="nofollow">The discovery of dicumarol and its sequels</a>". <i>Circulation</i> <b>19</b> (1): 97–107. <a href="http://www.ncbi.nlm.nih.gov/pubmed/13619027" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/13619027">PMID 13619027</a><span class="printonly">. <a href="http://circ.ahajournals.org/cgi/reprint/19/1/97" class="external free" title="http://circ.ahajournals.org/cgi/reprint/19/1/97" rel="nofollow">http://circ.ahajournals.org/cgi/reprint/19/1/97</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The+discovery+of+dicumarol+and+its+sequels&amp;rft.jtitle=Circulation&amp;rft.aulast=Link+KP&amp;rft.au=Link+KP&amp;rft.date=01%2F01%2F1959&amp;rft.volume=19&amp;rft.issue=1&amp;rft.pages=97%E2%80%93107&amp;rft_id=info:pmid/13619027&amp;rft_id=http%3A%2F%2Fcirc.ahajournals.org%2Fcgi%2Freprint%2F19%2F1%2F97&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Whitlon-6">^ <a href="#cite_ref-Whitlon_6-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Whitlon_6-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFWhitlon_DS.2C_Sadowski_JA.2C_Suttie_JW1978">Whitlon DS, Sadowski JA, Suttie JW (1978). "Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition". <i>Biochemistry</i> <b>17</b> (8): 1371–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1021%2Fbi00601a003" class="external text" title="http://dx.doi.org/10.1021%2Fbi00601a003" rel="nofollow">10.1021/bi00601a003</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/646989" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/646989">PMID 646989</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Mechanism+of+coumarin+action%3A+significance+of+vitamin+K+epoxide+reductase+inhibition&amp;rft.jtitle=Biochemistry&amp;rft.aulast=Whitlon+DS%2C+Sadowski+JA%2C+Suttie+JW&amp;rft.au=Whitlon+DS%2C+Sadowski+JA%2C+Suttie+JW&amp;rft.date=1978&amp;rft.volume=17&amp;rft.issue=8&amp;rft.pages=1371%E2%80%937&amp;rft_id=info:doi/10.1021%2Fbi00601a003&amp;rft_id=info:pmid/646989&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-7"><b><a href="#cite_ref-7" title="">^</a></b> <cite style="font-style:normal" class="book" id="CITEREFNaumov.2C_Vladimir_Pavlovich.3B_Brent.2C_Jonathan2003">Naumov, Vladimir Pavlovich; Brent, Jonathan (2003). <i>Stalin's last crime: the plot against the Jewish doctors, 1948–1953</i>. London: HarperCollins. <a href="/wiki/Special:BookSources/006019524X" class="internal">ISBN 0-06-019524-X</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Stalin%27s+last+crime%3A+the+plot+against+the+Jewish+doctors%2C+1948%E2%80%931953&amp;rft.aulast=Naumov%2C+Vladimir+Pavlovich%3B+Brent%2C+Jonathan&amp;rft.au=Naumov%2C+Vladimir+Pavlovich%3B+Brent%2C+Jonathan&amp;rft.date=2003&amp;rft.place=London&amp;rft.pub=HarperCollins&amp;rft.isbn=0-06-019524-X&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Hirsh-8">^ <a href="#cite_ref-Hirsh_8-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Hirsh_8-1" title=""><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Hirsh_8-2" title=""><sup><i><b>c</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFHirsh_J.2C_Fuster_V.2C_Ansell_J.2C_Halperin_JL2003">Hirsh J, Fuster V, Ansell J, Halperin JL (2003). "<a href="http://content.onlinejacc.org/cgi/content/full/41/9/1633" class="external text" title="http://content.onlinejacc.org/cgi/content/full/41/9/1633" rel="nofollow">American Heart Association/American College of Cardiology Foundation guide to warfarin therapy</a>". <i>J. Am. Coll. Cardiol.</i> <b>41</b> (9): 1633–52. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2FS0735-1097%2803%2900416-9" class="external text" title="http://dx.doi.org/10.1016%2FS0735-1097%2803%2900416-9" rel="nofollow">10.1016/S0735-1097(03)00416-9</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12742309" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12742309">PMID 12742309</a><span class="printonly">. <a href="http://content.onlinejacc.org/cgi/content/full/41/9/1633" class="external free" title="http://content.onlinejacc.org/cgi/content/full/41/9/1633" rel="nofollow">http://content.onlinejacc.org/cgi/content/full/41/9/1633</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=American+Heart+Association%2FAmerican+College+of+Cardiology+Foundation+guide+to+warfarin+therapy&amp;rft.jtitle=J.+Am.+Coll.+Cardiol.&amp;rft.aulast=Hirsh+J%2C+Fuster+V%2C+Ansell+J%2C+Halperin+JL&amp;rft.au=Hirsh+J%2C+Fuster+V%2C+Ansell+J%2C+Halperin+JL&amp;rft.date=2003&amp;rft.volume=41&amp;rft.issue=9&amp;rft.pages=1633%E2%80%9352&amp;rft_id=info:doi/10.1016%2FS0735-1097%2803%2900416-9&amp;rft_id=info:pmid/12742309&amp;rft_id=http%3A%2F%2Fcontent.onlinejacc.org%2Fcgi%2Fcontent%2Ffull%2F41%2F9%2F1633&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-9"><b><a href="#cite_ref-9" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFBaglin_TP.2C_Keeling_DM.2C_Watson_HG2006">Baglin TP, Keeling DM, Watson HG (February 2006). "<a href="http://www.blackwell-synergy.com/doi/pdf/10.1111/j.1365-2141.2006.06379.x" class="external text" title="http://www.blackwell-synergy.com/doi/pdf/10.1111/j.1365-2141.2006.06379.x" rel="nofollow">Guidelines on oral anticoagulation (warfarin): third edition—2005 update</a>". <i>Br. J. Haematol.</i> <b>132</b> (3): 277–85. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1111%2Fj.1365-2141.2005.05856.x" class="external text" title="http://dx.doi.org/10.1111%2Fj.1365-2141.2005.05856.x" rel="nofollow">10.1111/j.1365-2141.2005.05856.x</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16409292" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16409292">PMID 16409292</a><span class="printonly">. <a href="http://www.blackwell-synergy.com/doi/pdf/10.1111/j.1365-2141.2006.06379.x" class="external free" title="http://www.blackwell-synergy.com/doi/pdf/10.1111/j.1365-2141.2006.06379.x" rel="nofollow">http://www.blackwell-synergy.com/doi/pdf/10.1111/j.1365-2141.2006.06379.x</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Guidelines+on+oral+anticoagulation+%28warfarin%29%3A+third+edition%E2%80%942005+update&amp;rft.jtitle=Br.+J.+Haematol.&amp;rft.aulast=Baglin+TP%2C+Keeling+DM%2C+Watson+HG&amp;rft.au=Baglin+TP%2C+Keeling+DM%2C+Watson+HG&amp;rft.date=February+2006&amp;rft.volume=132&amp;rft.issue=3&amp;rft.pages=277%E2%80%9385&amp;rft_id=info:doi/10.1111%2Fj.1365-2141.2005.05856.x&amp;rft_id=info:pmid/16409292&amp;rft_id=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fpdf%2F10.1111%2Fj.1365-2141.2006.06379.x&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-10"><b><a href="#cite_ref-10" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFHirsh_J.2C_O.27Donnell_M.2C_Eikelboom_JW2007">Hirsh J, O'Donnell M, Eikelboom JW (July 2007). "<a href="http://circ.ahajournals.org/cgi/content/full/116/5/552" class="external text" title="http://circ.ahajournals.org/cgi/content/full/116/5/552" rel="nofollow">Beyond unfractionated heparin and warfarin: current and future advances</a>". <i>Circulation</i> <b>116</b> (5): 552–60. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1161%2FCIRCULATIONAHA.106.685974" class="external text" title="http://dx.doi.org/10.1161%2FCIRCULATIONAHA.106.685974" rel="nofollow">10.1161/CIRCULATIONAHA.106.685974</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17664384" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17664384">PMID 17664384</a><span class="printonly">. <a href="http://circ.ahajournals.org/cgi/content/full/116/5/552" class="external free" title="http://circ.ahajournals.org/cgi/content/full/116/5/552" rel="nofollow">http://circ.ahajournals.org/cgi/content/full/116/5/552</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Beyond+unfractionated+heparin+and+warfarin%3A+current+and+future+advances&amp;rft.jtitle=Circulation&amp;rft.aulast=Hirsh+J%2C+O%27Donnell+M%2C+Eikelboom+JW&amp;rft.au=Hirsh+J%2C+O%27Donnell+M%2C+Eikelboom+JW&amp;rft.date=July+2007&amp;rft.volume=116&amp;rft.issue=5&amp;rft.pages=552%E2%80%9360&amp;rft_id=info:doi/10.1161%2FCIRCULATIONAHA.106.685974&amp;rft_id=info:pmid/17664384&amp;rft_id=http%3A%2F%2Fcirc.ahajournals.org%2Fcgi%2Fcontent%2Ffull%2F116%2F5%2F552&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-HDT-11">^ <a href="#cite_ref-HDT_11-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-HDT_11-1" title=""><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-HDT_11-2" title=""><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-HDT_11-3" title=""><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-HDT_11-4" title=""><sup><i><b>e</b></i></sup></a> <cite style="font-style:normal" class="book" id="CITEREFMacina.2C_Orest_T..3B_Schardein.2C_James_L.2007">Macina, Orest T.; Schardein, James L. (2007). <a href="http://books.google.com/books?id=8_Lc58cGZj0C" class="external text" title="http://books.google.com/books?id=8_Lc58cGZj0C" rel="nofollow">"Warfarin"</a>. <i>Human Developmental Toxicants</i>. Boca Raton: CRC Taylor &amp; Francis. pp.&#160;193–4. <a href="/wiki/Special:BookSources/0849372291" class="internal">ISBN 0-8493-7229-1</a><span class="printonly">. <a href="http://books.google.com/books?id=8_Lc58cGZj0C" class="external free" title="http://books.google.com/books?id=8_Lc58cGZj0C" rel="nofollow">http://books.google.com/books?id=8_Lc58cGZj0C</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Warfarin&amp;rft.atitle=Human+Developmental+Toxicants&amp;rft.aulast=Macina%2C+Orest+T.%3B+Schardein%2C+James+L.&amp;rft.au=Macina%2C+Orest+T.%3B+Schardein%2C+James+L.&amp;rft.date=2007&amp;rft.pages=pp.%26nbsp%3B193%E2%80%934&amp;rft.place=Boca+Raton&amp;rft.pub=CRC+Taylor+%26+Francis&amp;rft.isbn=0-8493-7229-1&amp;rft_id=http%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3D8_Lc58cGZj0C&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span> Retrieved on December 15, 2008 through <a href="/wiki/Google_Book_Search" title="Google Book Search">Google Book Search</a>.</li>
<li id="cite_note-Loftus-12">^ <a href="#cite_ref-Loftus_12-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Loftus_12-1" title=""><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Loftus_12-2" title=""><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Loftus_12-3" title=""><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Loftus_12-4" title=""><sup><i><b>e</b></i></sup></a> <cite style="font-style:normal" class="book" id="CITEREFLoftus.2C_Christopher_M.1995">Loftus, Christopher M. (1995). <a href="http://books.google.com/books?id=X58R5BqtHmEC" class="external text" title="http://books.google.com/books?id=X58R5BqtHmEC" rel="nofollow">"Fetal toxicity of common neurosurgical drugs"</a>. <i>Neurosurgical Aspects of Pregnancy</i>. Park Ridge, Ill: American Association of Neurological Surgeons. pp.&#160;11–3. <a href="/wiki/Special:BookSources/1879284367" class="internal">ISBN 1-879284-36-7</a><span class="printonly">. <a href="http://books.google.com/books?id=X58R5BqtHmEC" class="external free" title="http://books.google.com/books?id=X58R5BqtHmEC" rel="nofollow">http://books.google.com/books?id=X58R5BqtHmEC</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Fetal+toxicity+of+common+neurosurgical+drugs&amp;rft.atitle=Neurosurgical+Aspects+of+Pregnancy&amp;rft.aulast=Loftus%2C+Christopher+M.&amp;rft.au=Loftus%2C+Christopher+M.&amp;rft.date=1995&amp;rft.pages=pp.%26nbsp%3B11%E2%80%933&amp;rft.place=Park+Ridge%2C+Ill&amp;rft.pub=American+Association+of+Neurological+Surgeons&amp;rft.isbn=1-879284-36-7&amp;rft_id=http%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DX58R5BqtHmEC&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Horton-13"><b><a href="#cite_ref-Horton_13-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFHorton_JD.2C_Bushwick_BM1999">Horton JD, Bushwick BM (February 1999). "<a href="http://www.aafp.org/afp/990201ap/635.html" class="external text" title="http://www.aafp.org/afp/990201ap/635.html" rel="nofollow">Warfarin therapy: evolving strategies in anticoagulation</a>". <i>Am Fam Physician</i> <b>59</b> (3): 635–46. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10029789" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/10029789">PMID 10029789</a><span class="printonly">. <a href="http://www.aafp.org/afp/990201ap/635.html" class="external free" title="http://www.aafp.org/afp/990201ap/635.html" rel="nofollow">http://www.aafp.org/afp/990201ap/635.html</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Warfarin+therapy%3A+evolving+strategies+in+anticoagulation&amp;rft.jtitle=Am+Fam+Physician&amp;rft.aulast=Horton+JD%2C+Bushwick+BM&amp;rft.au=Horton+JD%2C+Bushwick+BM&amp;rft.date=February+1999&amp;rft.volume=59&amp;rft.issue=3&amp;rft.pages=635%E2%80%9346&amp;rft_id=info:pmid/10029789&amp;rft_id=http%3A%2F%2Fwww.aafp.org%2Fafp%2F990201ap%2F635.html&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid17698822-14"><b><a href="#cite_ref-pmid17698822_14-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFDelaney_JA.2C_Opatrny_L.2C_Brophy_JM.2C_Suissa_S2007">Delaney JA, Opatrny L, Brophy JM, Suissa S (2007). "<a href="http://www.cmaj.ca/cgi/content/full/177/4/347" class="external text" title="http://www.cmaj.ca/cgi/content/full/177/4/347" rel="nofollow">Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding</a>". <i>CMAJ</i> <b>177</b> (4): 347–51. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1503%2Fcmaj.070186" class="external text" title="http://dx.doi.org/10.1503%2Fcmaj.070186" rel="nofollow">10.1503/cmaj.070186</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17698822" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17698822">PMID 17698822</a><span class="printonly">. <a href="http://www.cmaj.ca/cgi/content/full/177/4/347" class="external free" title="http://www.cmaj.ca/cgi/content/full/177/4/347" rel="nofollow">http://www.cmaj.ca/cgi/content/full/177/4/347</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Drug+drug+interactions+between+antithrombotic+medications+and+the+risk+of+gastrointestinal+bleeding&amp;rft.jtitle=CMAJ&amp;rft.aulast=Delaney+JA%2C+Opatrny+L%2C+Brophy+JM%2C+Suissa+S&amp;rft.au=Delaney+JA%2C+Opatrny+L%2C+Brophy+JM%2C+Suissa+S&amp;rft.date=2007&amp;rft.volume=177&amp;rft.issue=4&amp;rft.pages=347%E2%80%9351&amp;rft_id=info:doi/10.1503%2Fcmaj.070186&amp;rft_id=info:pmid/17698822&amp;rft_id=http%3A%2F%2Fwww.cmaj.ca%2Fcgi%2Fcontent%2Ffull%2F177%2F4%2F347&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span> Full text at <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>: <a href="http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1942107" class="external text" title="http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1942107" rel="nofollow">1942107</a></li>
<li id="cite_note-pmid17515465-15"><b><a href="#cite_ref-pmid17515465_15-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFHylek_EM.2C_Evans-Molina_C.2C_Shea_C.2C_Henault_LE.2C_Regan_S2007">Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007). "Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation". <i>Circulation</i> <b>115</b> (21): 2689–96. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1161%2FCIRCULATIONAHA.106.653048" class="external text" title="http://dx.doi.org/10.1161%2FCIRCULATIONAHA.106.653048" rel="nofollow">10.1161/CIRCULATIONAHA.106.653048</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17515465" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17515465">PMID 17515465</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Major+hemorrhage+and+tolerability+of+warfarin+in+the+first+year+of+therapy+among+elderly+patients+with+atrial+fibrillation&amp;rft.jtitle=Circulation&amp;rft.aulast=Hylek+EM%2C+Evans-Molina+C%2C+Shea+C%2C+Henault+LE%2C+Regan+S&amp;rft.au=Hylek+EM%2C+Evans-Molina+C%2C+Shea+C%2C+Henault+LE%2C+Regan+S&amp;rft.date=2007&amp;rft.volume=115&amp;rft.issue=21&amp;rft.pages=2689%E2%80%9396&amp;rft_id=info:doi/10.1161%2FCIRCULATIONAHA.106.653048&amp;rft_id=info:pmid/17515465&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid17720522-16"><b><a href="#cite_ref-pmid17720522_16-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFElliott_MJ.2C_Zimmerman_D.2C_Holden_RM2007">Elliott MJ, Zimmerman D, Holden RM (2007). "Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates". <i>Am. J. Kidney Dis.</i> <b>50</b> (3): 433–40. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1053%2Fj.ajkd.2007.06.017" class="external text" title="http://dx.doi.org/10.1053%2Fj.ajkd.2007.06.017" rel="nofollow">10.1053/j.ajkd.2007.06.017</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17720522" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17720522">PMID 17720522</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Warfarin+anticoagulation+in+hemodialysis+patients%3A+a+systematic+review+of+bleeding+rates&amp;rft.jtitle=Am.+J.+Kidney+Dis.&amp;rft.aulast=Elliott+MJ%2C+Zimmerman+D%2C+Holden+RM&amp;rft.au=Elliott+MJ%2C+Zimmerman+D%2C+Holden+RM&amp;rft.date=2007&amp;rft.volume=50&amp;rft.issue=3&amp;rft.pages=433%E2%80%9340&amp;rft_id=info:doi/10.1053%2Fj.ajkd.2007.06.017&amp;rft_id=info:pmid/17720522&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid10718793-17"><b><a href="#cite_ref-pmid10718793_17-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFChan_YC.2C_Valenti_D.2C_Mansfield_AO.2C_Stansby_G2000">Chan YC, Valenti D, Mansfield AO, Stansby G (2000). "Warfarin induced skin necrosis". <i>Br J Surg</i> <b>87</b> (3): 266–72. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1046%2Fj.1365-2168.2000.01352.x" class="external text" title="http://dx.doi.org/10.1046%2Fj.1365-2168.2000.01352.x" rel="nofollow">10.1046/j.1365-2168.2000.01352.x</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10718793" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/10718793">PMID 10718793</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Warfarin+induced+skin+necrosis&amp;rft.jtitle=Br+J+Surg&amp;rft.aulast=Chan+YC%2C+Valenti+D%2C+Mansfield+AO%2C+Stansby+G&amp;rft.au=Chan+YC%2C+Valenti+D%2C+Mansfield+AO%2C+Stansby+G&amp;rft.date=2000&amp;rft.volume=87&amp;rft.issue=3&amp;rft.pages=266%E2%80%9372&amp;rft_id=info:doi/10.1046%2Fj.1365-2168.2000.01352.x&amp;rft_id=info:pmid/10718793&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-18"><b><a href="#cite_ref-18" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFCaraballo_PJ.2C_Heit_JA.2C_Atkinson_EJ.2C_.27.27et_al.27.271999">Caraballo PJ, Heit JA, Atkinson EJ, <i>et al</i> (1999). "Long-term use of oral anticoagulants and the risk of fracture". <i>Arch. Intern. Med.</i> <b>159</b> (15): 1750–6. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1001%2Farchinte.159.15.1750" class="external text" title="http://dx.doi.org/10.1001%2Farchinte.159.15.1750" rel="nofollow">10.1001/archinte.159.15.1750</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10448778" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/10448778">PMID 10448778</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Long-term+use+of+oral+anticoagulants+and+the+risk+of+fracture&amp;rft.jtitle=Arch.+Intern.+Med.&amp;rft.aulast=Caraballo+PJ%2C+Heit+JA%2C+Atkinson+EJ%2C+%27%27et+al%27%27&amp;rft.au=Caraballo+PJ%2C+Heit+JA%2C+Atkinson+EJ%2C+%27%27et+al%27%27&amp;rft.date=1999&amp;rft.volume=159&amp;rft.issue=15&amp;rft.pages=1750%E2%80%936&amp;rft_id=info:doi/10.1001%2Farchinte.159.15.1750&amp;rft_id=info:pmid/10448778&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-19"><b><a href="#cite_ref-19" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFPilon_D.2C_Castilloux_AM.2C_Dorais_M.2C_LeLorier_J2004">Pilon D, Castilloux AM, Dorais M, LeLorier J (2004). "Oral anticoagulants and the risk of osteoporotic fractures among elderly". <i>Pharmacoepidemiol Drug Saf</i> <b>13</b> (5): 289–94. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1002%2Fpds.888" class="external text" title="http://dx.doi.org/10.1002%2Fpds.888" rel="nofollow">10.1002/pds.888</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15133779" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15133779">PMID 15133779</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Oral+anticoagulants+and+the+risk+of+osteoporotic+fractures+among+elderly&amp;rft.jtitle=Pharmacoepidemiol+Drug+Saf&amp;rft.aulast=Pilon+D%2C+Castilloux+AM%2C+Dorais+M%2C+LeLorier+J&amp;rft.au=Pilon+D%2C+Castilloux+AM%2C+Dorais+M%2C+LeLorier+J&amp;rft.date=2004&amp;rft.volume=13&amp;rft.issue=5&amp;rft.pages=289%E2%80%9394&amp;rft_id=info:doi/10.1002%2Fpds.888&amp;rft_id=info:pmid/15133779&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-20"><b><a href="#cite_ref-20" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFGage_BF.2C_Birman-Deych_E.2C_Radford_MJ.2C_Nilasena_DS.2C_Binder_EF2006">Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF (2006). "<a href="http://archinte.ama-assn.org/cgi/content/full/166/2/241" class="external text" title="http://archinte.ama-assn.org/cgi/content/full/166/2/241" rel="nofollow">Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2</a>". <i>Arch. Intern. Med.</i> <b>166</b> (2): 241–6. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1001%2Farchinte.166.2.241" class="external text" title="http://dx.doi.org/10.1001%2Farchinte.166.2.241" rel="nofollow">10.1001/archinte.166.2.241</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16432096" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16432096">PMID 16432096</a><span class="printonly">. <a href="http://archinte.ama-assn.org/cgi/content/full/166/2/241" class="external free" title="http://archinte.ama-assn.org/cgi/content/full/166/2/241" rel="nofollow">http://archinte.ama-assn.org/cgi/content/full/166/2/241</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Risk+of+osteoporotic+fracture+in+elderly+patients+taking+warfarin%3A+results+from+the+National+Registry+of+Atrial+Fibrillation+2&amp;rft.jtitle=Arch.+Intern.+Med.&amp;rft.aulast=Gage+BF%2C+Birman-Deych+E%2C+Radford+MJ%2C+Nilasena+DS%2C+Binder+EF&amp;rft.au=Gage+BF%2C+Birman-Deych+E%2C+Radford+MJ%2C+Nilasena+DS%2C+Binder+EF&amp;rft.date=2006&amp;rft.volume=166&amp;rft.issue=2&amp;rft.pages=241%E2%80%936&amp;rft_id=info:doi/10.1001%2Farchinte.166.2.241&amp;rft_id=info:pmid/16432096&amp;rft_id=http%3A%2F%2Farchinte.ama-assn.org%2Fcgi%2Fcontent%2Ffull%2F166%2F2%2F241&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-21"><b><a href="#cite_ref-21" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFTalmadge_DB.2C_Spyropoulos_AC2003">Talmadge DB, Spyropoulos AC (2003). "Purple toes syndrome associated with warfarin therapy in a patient with antiphospholipid syndrome". <i>Pharmacotherapy</i> <b>23</b> (5): 674–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1592%2Fphco.23.5.674.32200" class="external text" title="http://dx.doi.org/10.1592%2Fphco.23.5.674.32200" rel="nofollow">10.1592/phco.23.5.674.32200</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12741443" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12741443">PMID 12741443</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Purple+toes+syndrome+associated+with+warfarin+therapy+in+a+patient+with+antiphospholipid+syndrome&amp;rft.jtitle=Pharmacotherapy&amp;rft.aulast=Talmadge+DB%2C+Spyropoulos+AC&amp;rft.au=Talmadge+DB%2C+Spyropoulos+AC&amp;rft.date=2003&amp;rft.volume=23&amp;rft.issue=5&amp;rft.pages=674%E2%80%937&amp;rft_id=info:doi/10.1592%2Fphco.23.5.674.32200&amp;rft_id=info:pmid/12741443&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-22"><b><a href="#cite_ref-22" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFLi_T.2C_Chang_CY.2C_Jin_DY.2C_Lin_PJ.2C_Khvorova_A.2C_Stafford_DW2004">Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW (2004). "Identification of the gene for vitamin K epoxide reductase". <i>Nature</i> <b>427</b> (6974): 541–4. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1038%2Fnature02254" class="external text" title="http://dx.doi.org/10.1038%2Fnature02254" rel="nofollow">10.1038/nature02254</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14765195" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/14765195">PMID 14765195</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Identification+of+the+gene+for+vitamin+K+epoxide+reductase&amp;rft.jtitle=Nature&amp;rft.aulast=Li+T%2C+Chang+CY%2C+Jin+DY%2C+Lin+PJ%2C+Khvorova+A%2C+Stafford+DW&amp;rft.au=Li+T%2C+Chang+CY%2C+Jin+DY%2C+Lin+PJ%2C+Khvorova+A%2C+Stafford+DW&amp;rft.date=2004&amp;rft.volume=427&amp;rft.issue=6974&amp;rft.pages=541%E2%80%934&amp;rft_id=info:doi/10.1038%2Fnature02254&amp;rft_id=info:pmid/14765195&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid14765194-23">^ <a href="#cite_ref-pmid14765194_23-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid14765194_23-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFRost_S.2C_Fregin_A.2C_Ivaskevicius_V.2C_.27.27et_al.27.272004">Rost S, Fregin A, Ivaskevicius V, <i>et al</i> (2004). "Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2". <i>Nature</i> <b>427</b> (6974): 537–41. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1038%2Fnature02214" class="external text" title="http://dx.doi.org/10.1038%2Fnature02214" rel="nofollow">10.1038/nature02214</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14765194" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/14765194">PMID 14765194</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Mutations+in+VKORC1+cause+warfarin+resistance+and+multiple+coagulation+factor+deficiency+type+2&amp;rft.jtitle=Nature&amp;rft.aulast=Rost+S%2C+Fregin+A%2C+Ivaskevicius+V%2C+%27%27et+al%27%27&amp;rft.au=Rost+S%2C+Fregin+A%2C+Ivaskevicius+V%2C+%27%27et+al%27%27&amp;rft.date=2004&amp;rft.volume=427&amp;rft.issue=6974&amp;rft.pages=537%E2%80%9341&amp;rft_id=info:doi/10.1038%2Fnature02214&amp;rft_id=info:pmid/14765194&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid15383473-24">^ <a href="#cite_ref-pmid15383473_24-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid15383473_24-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFAnsell_J.2C_Hirsh_J.2C_Poller_L.2C_Bussey_H.2C_Jacobson_A.2C_Hylek_E2004">Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E (2004). "<a href="http://www.chestjournal.org/cgi/content/full/126/3_suppl/204S" class="external text" title="http://www.chestjournal.org/cgi/content/full/126/3_suppl/204S" rel="nofollow">The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy</a>". <i>Chest</i> <b>126</b> (3 Suppl): 204S–233S. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1378%2Fchest.126.3_suppl.204S" class="external text" title="http://dx.doi.org/10.1378%2Fchest.126.3_suppl.204S" rel="nofollow">10.1378/chest.126.3_suppl.204S</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15383473" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15383473">PMID 15383473</a><span class="printonly">. <a href="http://www.chestjournal.org/cgi/content/full/126/3_suppl/204S" class="external free" title="http://www.chestjournal.org/cgi/content/full/126/3_suppl/204S" rel="nofollow">http://www.chestjournal.org/cgi/content/full/126/3_suppl/204S</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The+pharmacology+and+management+of+the+vitamin+K+antagonists%3A+the+Seventh+ACCP+Conference+on+Antithrombotic+and+Thrombolytic+Therapy&amp;rft.jtitle=Chest&amp;rft.aulast=Ansell+J%2C+Hirsh+J%2C+Poller+L%2C+Bussey+H%2C+Jacobson+A%2C+Hylek+E&amp;rft.au=Ansell+J%2C+Hirsh+J%2C+Poller+L%2C+Bussey+H%2C+Jacobson+A%2C+Hylek+E&amp;rft.date=2004&amp;rft.volume=126&amp;rft.issue=3+Suppl&amp;rft.pages=204S%E2%80%93233S&amp;rft_id=info:doi/10.1378%2Fchest.126.3_suppl.204S&amp;rft_id=info:pmid/15383473&amp;rft_id=http%3A%2F%2Fwww.chestjournal.org%2Fcgi%2Fcontent%2Ffull%2F126%2F3_suppl%2F204S&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span> (<a href="http://www.chestjournal.org/cgi/content/full/126/3_suppl/204S/T6" class="external text" title="http://www.chestjournal.org/cgi/content/full/126/3_suppl/204S/T6" rel="nofollow">summary</a>)</li>
<li id="cite_note-pmid12186515-25"><b><a href="#cite_ref-pmid12186515_25-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFCrowther_MA.2C_Douketis_JD.2C_Schnurr_T.2C_.27.27et_al.27.272002">Crowther MA, Douketis JD, Schnurr T, <i>et al</i> (2002). "<a href="http://www.annals.org/cgi/reprint/137/4/251" class="external text" title="http://www.annals.org/cgi/reprint/137/4/251" rel="nofollow">Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial</a>" (PDF). <i>Ann. Intern. Med.</i> <b>137</b> (4): 251–4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12186515" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12186515">PMID 12186515</a><span class="printonly">. <a href="http://www.annals.org/cgi/reprint/137/4/251" class="external free" title="http://www.annals.org/cgi/reprint/137/4/251" rel="nofollow">http://www.annals.org/cgi/reprint/137/4/251</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Oral+vitamin+K+lowers+the+international+normalized+ratio+more+rapidly+than+subcutaneous+vitamin+K+in+the+treatment+of+warfarin-associated+coagulopathy.+A+randomized%2C+controlled+trial&amp;rft.jtitle=Ann.+Intern.+Med.&amp;rft.aulast=Crowther+MA%2C+Douketis+JD%2C+Schnurr+T%2C+%27%27et+al%27%27&amp;rft.au=Crowther+MA%2C+Douketis+JD%2C+Schnurr+T%2C+%27%27et+al%27%27&amp;rft.date=2002&amp;rft.volume=137&amp;rft.issue=4&amp;rft.pages=251%E2%80%934&amp;rft_id=info:pmid/12186515&amp;rft_id=http%3A%2F%2Fwww.annals.org%2Fcgi%2Freprint%2F137%2F4%2F251&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-26"><b><a href="#cite_ref-26" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://www.fda.gov/bbs/topics/NEWS/2007/NEW01684.html" class="external text" title="http://www.fda.gov/bbs/topics/NEWS/2007/NEW01684.html" rel="nofollow">"FDA Approves Updated Warfarin (Coumadin) Prescribing Information"</a><span class="printonly">. <a href="http://www.fda.gov/bbs/topics/NEWS/2007/NEW01684.html" class="external free" title="http://www.fda.gov/bbs/topics/NEWS/2007/NEW01684.html" rel="nofollow">http://www.fda.gov/bbs/topics/NEWS/2007/NEW01684.html</a></span><span class="reference-accessdate">. Retrieved on 2007-08-20</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=FDA+Approves+Updated+Warfarin+%28Coumadin%29+Prescribing+Information&amp;rft.atitle=&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2Fbbs%2Ftopics%2FNEWS%2F2007%2FNEW01684.html&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid15883587-27">^ <a href="#cite_ref-pmid15883587_27-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid15883587_27-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFWadelius_M.2C_Chen_LY.2C_Downes_K.2C_.27.27et_al.27.272005">Wadelius M, Chen LY, Downes K, <i>et al</i> (2005). "Common VKORC1 and GGCX polymorphisms associated with warfarin dose". <i>Pharmacogenomics J.</i> <b>5</b> (4): 262–70. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1038%2Fsj.tpj.6500313" class="external text" title="http://dx.doi.org/10.1038%2Fsj.tpj.6500313" rel="nofollow">10.1038/sj.tpj.6500313</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15883587" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15883587">PMID 15883587</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Common+VKORC1+and+GGCX+polymorphisms+associated+with+warfarin+dose&amp;rft.jtitle=Pharmacogenomics+J.&amp;rft.aulast=Wadelius+M%2C+Chen+LY%2C+Downes+K%2C+%27%27et+al%27%27&amp;rft.au=Wadelius+M%2C+Chen+LY%2C+Downes+K%2C+%27%27et+al%27%27&amp;rft.date=2005&amp;rft.volume=5&amp;rft.issue=4&amp;rft.pages=262%E2%80%9370&amp;rft_id=info:doi/10.1038%2Fsj.tpj.6500313&amp;rft_id=info:pmid/15883587&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid15930419-28">^ <a href="#cite_ref-pmid15930419_28-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid15930419_28-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFRieder_MJ.2C_Reiner_AP.2C_Gage_BF.2C_.27.27et_al.27.272005">Rieder MJ, Reiner AP, Gage BF, <i>et al</i> (2005). "Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose". <i>N. Engl. J. Med.</i> <b>352</b> (22): 2285–93. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1056%2FNEJMoa044503" class="external text" title="http://dx.doi.org/10.1056%2FNEJMoa044503" rel="nofollow">10.1056/NEJMoa044503</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15930419" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15930419">PMID 15930419</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Effect+of+VKORC1+haplotypes+on+transcriptional+regulation+and+warfarin+dose&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.aulast=Rieder+MJ%2C+Reiner+AP%2C+Gage+BF%2C+%27%27et+al%27%27&amp;rft.au=Rieder+MJ%2C+Reiner+AP%2C+Gage+BF%2C+%27%27et+al%27%27&amp;rft.date=2005&amp;rft.volume=352&amp;rft.issue=22&amp;rft.pages=2285%E2%80%9393&amp;rft_id=info:doi/10.1056%2FNEJMoa044503&amp;rft_id=info:pmid/15930419&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid18322281-29">^ <a href="#cite_ref-pmid18322281_29-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid18322281_29-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFSchwarz_UI.2C_Ritchie_MD.2C_Bradford_Y.2C_.27.27et_al.27.272008">Schwarz UI, Ritchie MD, Bradford Y, <i>et al</i> (2008). "Genetic determinants of response to warfarin during initial anticoagulation". <i>N. Engl. J. Med.</i> <b>358</b> (10): 999–1008. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1056%2FNEJMoa0708078" class="external text" title="http://dx.doi.org/10.1056%2FNEJMoa0708078" rel="nofollow">10.1056/NEJMoa0708078</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18322281" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/18322281">PMID 18322281</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Genetic+determinants+of+response+to+warfarin+during+initial+anticoagulation&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.aulast=Schwarz+UI%2C+Ritchie+MD%2C+Bradford+Y%2C+%27%27et+al%27%27&amp;rft.au=Schwarz+UI%2C+Ritchie+MD%2C+Bradford+Y%2C+%27%27et+al%27%27&amp;rft.date=2008&amp;rft.volume=358&amp;rft.issue=10&amp;rft.pages=999%E2%80%931008&amp;rft_id=info:doi/10.1056%2FNEJMoa0708078&amp;rft_id=info:pmid/18322281&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid15714076-30"><b><a href="#cite_ref-pmid15714076_30-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFSanderson_S.2C_Emery_J.2C_Higgins_J2005">Sanderson S, Emery J, Higgins J (2005). "CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis". <i>Genet. Med.</i> <b>7</b> (2): 97–104. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1002%2Fajmg.a.30391" class="external text" title="http://dx.doi.org/10.1002%2Fajmg.a.30391" rel="nofollow">10.1002/ajmg.a.30391</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15714076" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15714076">PMID 15714076</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=CYP2C9+gene+variants%2C+drug+dose%2C+and+bleeding+risk+in+warfarin-treated+patients%3A+a+HuGEnet+systematic+review+and+meta-analysis&amp;rft.jtitle=Genet.+Med.&amp;rft.aulast=Sanderson+S%2C+Emery+J%2C+Higgins+J&amp;rft.au=Sanderson+S%2C+Emery+J%2C+Higgins+J&amp;rft.date=2005&amp;rft.volume=7&amp;rft.issue=2&amp;rft.pages=97%E2%80%93104&amp;rft_id=info:doi/10.1002%2Fajmg.a.30391&amp;rft_id=info:pmid/15714076&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid12729425-31"><b><a href="#cite_ref-pmid12729425_31-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFKovacs_MJ.2C_Rodger_M.2C_Anderson_DR.2C_.27.27et_al.27.272003">Kovacs MJ, Rodger M, Anderson DR, <i>et al</i> (2003). "<a href="http://annals.org/cgi/content/full/138/9/714" class="external text" title="http://annals.org/cgi/content/full/138/9/714" rel="nofollow">Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial</a>". <i>Ann. Intern. Med.</i> <b>138</b> (9): 714–9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12729425" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12729425">PMID 12729425</a><span class="printonly">. <a href="http://annals.org/cgi/content/full/138/9/714" class="external free" title="http://annals.org/cgi/content/full/138/9/714" rel="nofollow">http://annals.org/cgi/content/full/138/9/714</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Comparison+of+10-mg+and+5-mg+warfarin+initiation+nomograms+together+with+low-molecular-weight+heparin+for+outpatient+treatment+of+acute+venous+thromboembolism.+A+randomized%2C+double-blind%2C+controlled+trial&amp;rft.jtitle=Ann.+Intern.+Med.&amp;rft.aulast=Kovacs+MJ%2C+Rodger+M%2C+Anderson+DR%2C+%27%27et+al%27%27&amp;rft.au=Kovacs+MJ%2C+Rodger+M%2C+Anderson+DR%2C+%27%27et+al%27%27&amp;rft.date=2003&amp;rft.volume=138&amp;rft.issue=9&amp;rft.pages=714%E2%80%939&amp;rft_id=info:pmid/12729425&amp;rft_id=http%3A%2F%2Fannals.org%2Fcgi%2Fcontent%2Ffull%2F138%2F9%2F714&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span> (<a href="http://annals.org/cgi/content/full/138/9/714/F1" class="external text" title="http://annals.org/cgi/content/full/138/9/714/F1" rel="nofollow">summary of 10 mg algorithm</a>)</li>
<li id="cite_note-pmid3144365-32"><b><a href="#cite_ref-pmid3144365_32-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFFennerty_A.2C_Campbell_IA.2C_Routledge_PA1988">Fennerty A, Campbell IA, Routledge PA (1988). "Anticoagulants in venous thromboembolism". <i>BMJ</i> <b>297</b> (6659): 1285–8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3144365" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/3144365">PMID 3144365</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Anticoagulants+in+venous+thromboembolism&amp;rft.jtitle=BMJ&amp;rft.aulast=Fennerty+A%2C+Campbell+IA%2C+Routledge+PA&amp;rft.au=Fennerty+A%2C+Campbell+IA%2C+Routledge+PA&amp;rft.date=1988&amp;rft.volume=297&amp;rft.issue=6659&amp;rft.pages=1285%E2%80%938&amp;rft_id=info:pmid/3144365&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span> Full text at <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>: <a href="http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1834928" class="external text" title="http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1834928" rel="nofollow">1834928</a></li>
<li id="cite_note-pmid9633885-33"><b><a href="#cite_ref-pmid9633885_33-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFTait_RC.2C_Sefcick_A1998">Tait RC, Sefcick A (1998). "A warfarin induction regimen for out-patient anticoagulation in patients with atrial fibrillation". <i>Br. J. Haematol.</i> <b>101</b> (3): 450–4. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1046%2Fj.1365-2141.1998.00716.x" class="external text" title="http://dx.doi.org/10.1046%2Fj.1365-2141.1998.00716.x" rel="nofollow">10.1046/j.1365-2141.1998.00716.x</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9633885" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9633885">PMID 9633885</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=A+warfarin+induction+regimen+for+out-patient+anticoagulation+in+patients+with+atrial+fibrillation&amp;rft.jtitle=Br.+J.+Haematol.&amp;rft.aulast=Tait+RC%2C+Sefcick+A&amp;rft.au=Tait+RC%2C+Sefcick+A&amp;rft.date=1998&amp;rft.volume=101&amp;rft.issue=3&amp;rft.pages=450%E2%80%934&amp;rft_id=info:doi/10.1046%2Fj.1365-2141.1998.00716.x&amp;rft_id=info:pmid/9633885&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span> <a href="http://www.blackwell-synergy.com/action/showPopup?citid=citart1&amp;id=f1&amp;doi=10.1046%2Fj.1365-2141.1998.00716.x" class="external text" title="http://www.blackwell-synergy.com/action/showPopup?citid=citart1&amp;id=f1&amp;doi=10.1046%2Fj.1365-2141.1998.00716.x" rel="nofollow">summary</a></li>
<li id="cite_note-34"><b><a href="#cite_ref-34" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFMillican_E.2C_Jacobsen-Lenzini_PA.2C_Milligan_PE.2C_.27.27et_al.27.272007">Millican E, Jacobsen-Lenzini PA, Milligan PE, <i>et al</i> (2007). "Genetic-based dosing in orthopaedic patients beginning warfarin therapy". <i>Blood</i> <b>110</b> (5): 1511–5. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1182%2Fblood-2007-01-069609" class="external text" title="http://dx.doi.org/10.1182%2Fblood-2007-01-069609" rel="nofollow">10.1182/blood-2007-01-069609</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17387222" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17387222">PMID 17387222</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Genetic-based+dosing+in+orthopaedic+patients+beginning+warfarin+therapy&amp;rft.jtitle=Blood&amp;rft.aulast=Millican+E%2C+Jacobsen-Lenzini+PA%2C+Milligan+PE%2C+%27%27et+al%27%27&amp;rft.au=Millican+E%2C+Jacobsen-Lenzini+PA%2C+Milligan+PE%2C+%27%27et+al%27%27&amp;rft.date=2007&amp;rft.volume=110&amp;rft.issue=5&amp;rft.pages=1511%E2%80%935&amp;rft_id=info:doi/10.1182%2Fblood-2007-01-069609&amp;rft_id=info:pmid/17387222&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span>.</li>
<li id="cite_note-35"><b><a href="#cite_ref-35" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFLenzini_PA.2C_Grice_GR.2C_Milligan_PE.2C_.27.27et_al.27.272008">Lenzini PA, Grice GR, Milligan PE, <i>et al</i> (2008). "Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients". <i>Journal of Thrombosis and Haemostasis</i> <b>6</b>: 1–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1111%2Fj.1538-7836.2008.03095x" class="external text" title="http://dx.doi.org/10.1111%2Fj.1538-7836.2008.03095x" rel="nofollow">10.1111/j.1538-7836.2008.03095x</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Laboratory+and+clinical+outcomes+of+pharmacogenetic+vs.+clinical+protocols+for+warfarin+initiation+in+orthopedic+patients&amp;rft.jtitle=Journal+of+Thrombosis+and+Haemostasis&amp;rft.aulast=Lenzini+PA%2C+Grice+GR%2C+Milligan+PE%2C+%27%27et+al%27%27&amp;rft.au=Lenzini+PA%2C+Grice+GR%2C+Milligan+PE%2C+%27%27et+al%27%27&amp;rft.date=2008&amp;rft.volume=6&amp;rft.pages=1%E2%80%938&amp;rft_id=info:doi/10.1111%2Fj.1538-7836.2008.03095x&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span> <a href="http://www.warfarindosing.org" class="external text" title="http://www.warfarindosing.org" rel="nofollow">Online tool based on the study</a>.</li>
<li id="cite_note-36"><b><a href="#cite_ref-36" title="">^</a></b> <a href="http://www.warfarindosing.org" class="external text" title="http://www.warfarindosing.org" rel="nofollow">Online tool based on the study</a>.</li>
<li id="cite_note-37"><b><a href="#cite_ref-37" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://www.aafp.org/afp/20050515/pocform.html" class="external text" title="http://www.aafp.org/afp/20050515/pocform.html" rel="nofollow">"Point-of-Care Guides: May 15, 2005. American Family Physician"</a><span class="printonly">. <a href="http://www.aafp.org/afp/20050515/pocform.html" class="external free" title="http://www.aafp.org/afp/20050515/pocform.html" rel="nofollow">http://www.aafp.org/afp/20050515/pocform.html</a></span><span class="reference-accessdate">. Retrieved on 2007-08-20</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Point-of-Care+Guides%3A+May+15%2C+2005.+American+Family+Physician&amp;rft.atitle=&amp;rft_id=http%3A%2F%2Fwww.aafp.org%2Fafp%2F20050515%2Fpocform.html&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Ansell_2005-38"><b><a href="#cite_ref-Ansell_2005_38-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFAnsell_J.2C_Jacobson_A.2C_Levy_J.2C_V.C3.B6ller_H.2C_Hasenkam_JM2005">Ansell J, Jacobson A, Levy J, Völler H, Hasenkam JM (March 2005). "Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation". <i>Int. J. Cardiol.</i> <b>99</b> (1): 37–45. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2Fj.ijcard.2003.11.008" class="external text" title="http://dx.doi.org/10.1016%2Fj.ijcard.2003.11.008" rel="nofollow">10.1016/j.ijcard.2003.11.008</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15721497" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15721497">PMID 15721497</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Guidelines+for+implementation+of+patient+self-testing+and+patient+self-management+of+oral+anticoagulation.+International+consensus+guidelines+prepared+by+International+Self-Monitoring+Association+for+Oral+Anticoagulation&amp;rft.jtitle=Int.+J.+Cardiol.&amp;rft.aulast=Ansell+J%2C+Jacobson+A%2C+Levy+J%2C+V%C3%B6ller+H%2C+Hasenkam+JM&amp;rft.au=Ansell+J%2C+Jacobson+A%2C+Levy+J%2C+V%C3%B6ller+H%2C+Hasenkam+JM&amp;rft.date=March+2005&amp;rft.volume=99&amp;rft.issue=1&amp;rft.pages=37%E2%80%9345&amp;rft_id=info:doi/10.1016%2Fj.ijcard.2003.11.008&amp;rft_id=info:pmid/15721497&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-39"><b><a href="#cite_ref-39" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFGage_BF.2C_Fihn_SD.2C_White_RH2000">Gage BF, Fihn SD, White RH (October 2000). "Management and dosing of warfarin therapy". <i>Am. J. Med.</i> <b>109</b> (6): 481–8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11042238" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11042238">PMID 11042238</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Management+and+dosing+of+warfarin+therapy&amp;rft.jtitle=Am.+J.+Med.&amp;rft.aulast=Gage+BF%2C+Fihn+SD%2C+White+RH&amp;rft.au=Gage+BF%2C+Fihn+SD%2C+White+RH&amp;rft.date=October+2000&amp;rft.volume=109&amp;rft.issue=6&amp;rft.pages=481%E2%80%938&amp;rft_id=info:pmid/11042238&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Juurlink-40"><b><a href="#cite_ref-Juurlink_40-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFJuurlink_DN2007">Juurlink DN (August 2007). "<a href="http://www.cmaj.ca/cgi/content/full/177/4/369" class="external text" title="http://www.cmaj.ca/cgi/content/full/177/4/369" rel="nofollow">Drug interactions with warfarin: what clinicians need to know</a>". <i>CMAJ</i> <b>177</b> (4): 369–71. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1503%2Fcmaj.070946" class="external text" title="http://dx.doi.org/10.1503%2Fcmaj.070946" rel="nofollow">10.1503/cmaj.070946</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17698826" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17698826">PMID 17698826</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>: <a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1942100" class="external text" title="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1942100" rel="nofollow">1942100</a><span class="printonly">. <a href="http://www.cmaj.ca/cgi/content/full/177/4/369" class="external free" title="http://www.cmaj.ca/cgi/content/full/177/4/369" rel="nofollow">http://www.cmaj.ca/cgi/content/full/177/4/369</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Drug+interactions+with+warfarin%3A+what+clinicians+need+to+know&amp;rft.jtitle=CMAJ&amp;rft.aulast=Juurlink+DN&amp;rft.au=Juurlink+DN&amp;rft.date=August+2007&amp;rft.volume=177&amp;rft.issue=4&amp;rft.pages=369%E2%80%9371&amp;rft_id=info:doi/10.1503%2Fcmaj.070946&amp;rft_id=info:pmid/17698826&amp;rft_id=http%3A%2F%2Fwww.cmaj.ca%2Fcgi%2Fcontent%2Ffull%2F177%2F4%2F369&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Kurnik-41">^ <a href="#cite_ref-Kurnik_41-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Kurnik_41-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFKurnik_D.2C_Loebstein_R.2C_Farfel_Z.2C_Ezra_D.2C_Halkin_H.2C_Olchovsky_D2004">Kurnik D, Loebstein R, Farfel Z, Ezra D, Halkin H, Olchovsky D (March 2004). "<a href="http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0025-7974&amp;volume=83&amp;issue=2&amp;spage=107" class="external text" title="http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0025-7974&amp;volume=83&amp;issue=2&amp;spage=107" rel="nofollow">Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland</a>". <i>Medicine (Baltimore)</i> <b>83</b> (2): 107–13. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1097%2F01.md.0000123095.65294.34" class="external text" title="http://dx.doi.org/10.1097%2F01.md.0000123095.65294.34" rel="nofollow">10.1097/01.md.0000123095.65294.34</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15028964" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15028964">PMID 15028964</a><span class="printonly">. <a href="http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0025-7974&amp;volume=83&amp;issue=2&amp;spage=107" class="external free" title="http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0025-7974&amp;volume=83&amp;issue=2&amp;spage=107" rel="nofollow">http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0025-7974&amp;volume=83&amp;issue=2&amp;spage=107</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Complex+drug-drug-disease+interactions+between+amiodarone%2C+warfarin%2C+and+the+thyroid+gland&amp;rft.jtitle=Medicine+%28Baltimore%29&amp;rft.aulast=Kurnik+D%2C+Loebstein+R%2C+Farfel+Z%2C+Ezra+D%2C+Halkin+H%2C+Olchovsky+D&amp;rft.au=Kurnik+D%2C+Loebstein+R%2C+Farfel+Z%2C+Ezra+D%2C+Halkin+H%2C+Olchovsky+D&amp;rft.date=March+2004&amp;rft.volume=83&amp;rft.issue=2&amp;rft.pages=107%E2%80%9313&amp;rft_id=info:doi/10.1097%2F01.md.0000123095.65294.34&amp;rft_id=info:pmid/15028964&amp;rft_id=http%3A%2F%2Fmeta.wkhealth.com%2Fpt%2Fpt-core%2Ftemplate-journal%2Flwwgateway%2Fmedia%2Flandingpage.htm%3Fissn%3D0025-7974%26volume%3D83%26issue%3D2%26spage%3D107&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-42"><b><a href="#cite_ref-42" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFStephens_MA.2C_Self_TH.2C_Lancaster_D.2C_Nash_T1989">Stephens MA, Self TH, Lancaster D, Nash T (December 1989). "<a href="http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0038-4348&amp;volume=82&amp;issue=12&amp;spage=1585" class="external text" title="http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0038-4348&amp;volume=82&amp;issue=12&amp;spage=1585" rel="nofollow">Hypothyroidism: effect on warfarin anticoagulation</a>". <i>South Med J</i> <b>82</b> (12): 1585–6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2595433" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/2595433">PMID 2595433</a><span class="printonly">. <a href="http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0038-4348&amp;volume=82&amp;issue=12&amp;spage=1585" class="external free" title="http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0038-4348&amp;volume=82&amp;issue=12&amp;spage=1585" rel="nofollow">http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0038-4348&amp;volume=82&amp;issue=12&amp;spage=1585</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Hypothyroidism%3A+effect+on+warfarin+anticoagulation&amp;rft.jtitle=South+Med+J&amp;rft.aulast=Stephens+MA%2C+Self+TH%2C+Lancaster+D%2C+Nash+T&amp;rft.au=Stephens+MA%2C+Self+TH%2C+Lancaster+D%2C+Nash+T&amp;rft.date=December+1989&amp;rft.volume=82&amp;rft.issue=12&amp;rft.pages=1585%E2%80%936&amp;rft_id=info:pmid/2595433&amp;rft_id=http%3A%2F%2Fmeta.wkhealth.com%2Fpt%2Fpt-core%2Ftemplate-journal%2Flwwgateway%2Fmedia%2Flandingpage.htm%3Fissn%3D0038-4348%26volume%3D82%26issue%3D12%26spage%3D1585&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-43"><b><a href="#cite_ref-43" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFChute_JP.2C_Ryan_CP.2C_Sladek_G.2C_Shakir_KM1997">Chute JP, Ryan CP, Sladek G, Shakir KM (1997). "<a href="http://aace.metapress.com/openurl.asp?genre=article&amp;issn=1530-891X&amp;volume=3&amp;issue=2&amp;spage=77" class="external text" title="http://aace.metapress.com/openurl.asp?genre=article&amp;issn=1530-891X&amp;volume=3&amp;issue=2&amp;spage=77" rel="nofollow">Exacerbation of warfarin-induced anticoagulation by hyperthyroidism</a>". <i>Endocr Pract</i> <b>3</b> (2): 77–9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15251480" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15251480">PMID 15251480</a><span class="printonly">. <a href="http://aace.metapress.com/openurl.asp?genre=article&amp;issn=1530-891X&amp;volume=3&amp;issue=2&amp;spage=77" class="external free" title="http://aace.metapress.com/openurl.asp?genre=article&amp;issn=1530-891X&amp;volume=3&amp;issue=2&amp;spage=77" rel="nofollow">http://aace.metapress.com/openurl.asp?genre=article&amp;issn=1530-891X&amp;volume=3&amp;issue=2&amp;spage=77</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Exacerbation+of+warfarin-induced+anticoagulation+by+hyperthyroidism&amp;rft.jtitle=Endocr+Pract&amp;rft.aulast=Chute+JP%2C+Ryan+CP%2C+Sladek+G%2C+Shakir+KM&amp;rft.au=Chute+JP%2C+Ryan+CP%2C+Sladek+G%2C+Shakir+KM&amp;rft.date=1997&amp;rft.volume=3&amp;rft.issue=2&amp;rft.pages=77%E2%80%939&amp;rft_id=info:pmid/15251480&amp;rft_id=http%3A%2F%2Faace.metapress.com%2Fopenurl.asp%3Fgenre%3Darticle%26issn%3D1530-891X%26volume%3D3%26issue%3D2%26spage%3D77&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-44"><b><a href="#cite_ref-44" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFKellett_HA.2C_Sawers_JS.2C_Boulton_FE.2C_Cholerton_S.2C_Park_BK.2C_Toft_AD1986">Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD (January 1986). "<a href="http://qjmed.oxfordjournals.org/cgi/pmidlookup?view=long&amp;pmid=3704105" class="external text" title="http://qjmed.oxfordjournals.org/cgi/pmidlookup?view=long&amp;pmid=3704105" rel="nofollow">Problems of anticoagulation with warfarin in hyperthyroidism</a>". <i>Q J Med</i> <b>58</b> (225): 43–51. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3704105" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/3704105">PMID 3704105</a><span class="printonly">. <a href="http://qjmed.oxfordjournals.org/cgi/pmidlookup?view=long&amp;pmid=3704105" class="external free" title="http://qjmed.oxfordjournals.org/cgi/pmidlookup?view=long&amp;pmid=3704105" rel="nofollow">http://qjmed.oxfordjournals.org/cgi/pmidlookup?view=long&amp;pmid=3704105</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Problems+of+anticoagulation+with+warfarin+in+hyperthyroidism&amp;rft.jtitle=Q+J+Med&amp;rft.aulast=Kellett+HA%2C+Sawers+JS%2C+Boulton+FE%2C+Cholerton+S%2C+Park+BK%2C+Toft+AD&amp;rft.au=Kellett+HA%2C+Sawers+JS%2C+Boulton+FE%2C+Cholerton+S%2C+Park+BK%2C+Toft+AD&amp;rft.date=January+1986&amp;rft.volume=58&amp;rft.issue=225&amp;rft.pages=43%E2%80%9351&amp;rft_id=info:pmid/3704105&amp;rft_id=http%3A%2F%2Fqjmed.oxfordjournals.org%2Fcgi%2Fpmidlookup%3Fview%3Dlong%26pmid%3D3704105&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-45"><b><a href="#cite_ref-45" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFWeathermon_R.2C_Crabb_DW1999">Weathermon R, Crabb DW (1999). "Alcohol and medication interactions". <i>Alcohol Res Health</i> <b>23</b> (1): 40–54. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10890797" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/10890797">PMID 10890797</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Alcohol+and+medication+interactions&amp;rft.jtitle=Alcohol+Res+Health&amp;rft.aulast=Weathermon+R%2C+Crabb+DW&amp;rft.au=Weathermon+R%2C+Crabb+DW&amp;rft.date=1999&amp;rft.volume=23&amp;rft.issue=1&amp;rft.pages=40%E2%80%9354&amp;rft_id=info:pmid/10890797&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-drug-herb-46"><b><a href="#cite_ref-drug-herb_46-0" title="">^</a></b> <cite style="font-style:normal" class="book" id="CITEREFAustin.2C_Steve_and_Batz.2C_Forrest1999">Austin, Steve and Batz, Forrest (1999). Lininger, Schuyler W.. ed. <i>A-Z guide to drug-herb-vitamin interactions: how to improve your health and avoid problems when using common medications and natural supplements together</i>. Roseville, Calif: Prima Health. pp.&#160;224. <a href="/wiki/Special:BookSources/0761515992" class="internal">ISBN 0-7615-1599-2</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=A-Z+guide+to+drug-herb-vitamin+interactions%3A+how+to+improve+your+health+and+avoid+problems+when+using+common+medications+and+natural+supplements+together&amp;rft.aulast=Austin%2C+Steve+and+Batz%2C+Forrest&amp;rft.au=Austin%2C+Steve+and+Batz%2C+Forrest&amp;rft.date=1999&amp;rft.pages=pp.%26nbsp%3B224&amp;rft.place=Roseville%2C+Calif&amp;rft.pub=Prima+Health&amp;rft.isbn=0-7615-1599-2&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-47"><b><a href="#cite_ref-47" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://www.rpsgb.org/pdfs/libnewadd0802.pdf" class="external text" title="http://www.rpsgb.org/pdfs/libnewadd0802.pdf" rel="nofollow">"Information Pharmacists’ news"</a>. written at 1 Lambeth High Street, London SE1 7JN (PDF). <i>Information Centre Bulletin</i>. <a href="/wiki/Royal_Pharmaceutical_Society_of_Great_Britain" title="Royal Pharmaceutical Society of Great Britain">Royal Pharmaceutical Society of Great Britain</a>. February 2008. pp 1<span class="printonly">. <a href="http://www.rpsgb.org/pdfs/libnewadd0802.pdf" class="external free" title="http://www.rpsgb.org/pdfs/libnewadd0802.pdf" rel="nofollow">http://www.rpsgb.org/pdfs/libnewadd0802.pdf</a></span><span class="reference-accessdate">. Retrieved on 14 January 2009</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Information+Pharmacists%E2%80%99+news&amp;rft.atitle=Information+Centre+Bulletin&amp;rft.date=February+2008&amp;rft.pages=pp+1&amp;rft.pub=%5B%5BRoyal+Pharmaceutical+Society+of+Great+Britain%5D%5D&amp;rft_id=http%3A%2F%2Fwww.rpsgb.org%2Fpdfs%2Flibnewadd0802.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-48"><b><a href="#cite_ref-48" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREFDr_Jo_Barnes_BPharm_MRPharmSWorking_Group_on_Complementary_Medicine2002">Dr Jo Barnes BPharm MRPharmS; Working Group on Complementary Medicine (September 2002). <a href="http://www.rpsgb.org.uk/pdfs/scifactsheetstjwort.pdf" class="external text" title="http://www.rpsgb.org.uk/pdfs/scifactsheetstjwort.pdf" rel="nofollow">"Herb-medicine interactions: St John’s Wort (Hypericum perforatum) Useful information for pharmacist"</a>. written at 1 Lambeth High Street, London SE1 7JN (PDF). <a href="/wiki/Royal_Pharmaceutical_Society_of_Great_Britain" title="Royal Pharmaceutical Society of Great Britain">Royal Pharmaceutical Society of Great Britain</a>. pp 5<span class="printonly">. <a href="http://www.rpsgb.org.uk/pdfs/scifactsheetstjwort.pdf" class="external free" title="http://www.rpsgb.org.uk/pdfs/scifactsheetstjwort.pdf" rel="nofollow">http://www.rpsgb.org.uk/pdfs/scifactsheetstjwort.pdf</a></span><span class="reference-accessdate">. Retrieved on 14 January 2009</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Herb-medicine+interactions%3A+St+John%E2%80%99s+Wort+%28Hypericum+perforatum%29+Useful+information+for+pharmacist&amp;rft.atitle=&amp;rft.aulast=Dr+Jo+Barnes+BPharm+MRPharmS&amp;rft.au=Dr+Jo+Barnes+BPharm+MRPharmS&amp;rft.au=Working+Group+on+Complementary+Medicine&amp;rft.date=September+2002&amp;rft.pages=pp+5&amp;rft.pub=%5B%5BRoyal+Pharmaceutical+Society+of+Great+Britain%5D%5D&amp;rft_id=http%3A%2F%2Fwww.rpsgb.org.uk%2Fpdfs%2Fscifactsheetstjwort.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-49"><b><a href="#cite_ref-49" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://news.bbc.co.uk/1/hi/health/3120206.stm" class="external text" title="http://news.bbc.co.uk/1/hi/health/3120206.stm" rel="nofollow">"Cranberry juice clot drug warning"</a>. <i>BBC news</i>. 2003-09-18<span class="printonly">. <a href="http://news.bbc.co.uk/1/hi/health/3120206.stm" class="external free" title="http://news.bbc.co.uk/1/hi/health/3120206.stm" rel="nofollow">http://news.bbc.co.uk/1/hi/health/3120206.stm</a></span><span class="reference-accessdate">. Retrieved on 2008-05-18</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Cranberry+juice+clot+drug+warning&amp;rft.atitle=BBC+news&amp;rft.date=2003-09-18&amp;rft_id=http%3A%2F%2Fnews.bbc.co.uk%2F1%2Fhi%2Fhealth%2F3120206.stm&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Suvarna-50"><b><a href="#cite_ref-Suvarna_50-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFSuvarna_R.2C_Pirmohamed_M.2C_Henderson_L2003">Suvarna R, Pirmohamed M, Henderson L (December 2003). "<a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=300803" class="external text" title="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=300803" rel="nofollow">Possible interaction between warfarin and cranberry juice</a>". <i>BMJ</i> <b>327</b> (7429): 1454. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1136%2Fbmj.327.7429.1454" class="external text" title="http://dx.doi.org/10.1136%2Fbmj.327.7429.1454" rel="nofollow">10.1136/bmj.327.7429.1454</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14684645" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/14684645">PMID 14684645</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Possible+interaction+between+warfarin+and+cranberry+juice&amp;rft.jtitle=BMJ&amp;rft.aulast=Suvarna+R%2C+Pirmohamed+M%2C+Henderson+L&amp;rft.au=Suvarna+R%2C+Pirmohamed+M%2C+Henderson+L&amp;rft.date=December+2003&amp;rft.volume=327&amp;rft.issue=7429&amp;rft.pages=1454&amp;rft_id=info:doi/10.1136%2Fbmj.327.7429.1454&amp;rft_id=info:pmid/14684645&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Aston-51">^ <a href="#cite_ref-Aston_51-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Aston_51-1" title=""><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Aston_51-2" title=""><sup><i><b>c</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFAston_JL.2C_Lodolce_AE.2C_Shapiro_NL2006">Aston JL, Lodolce AE, Shapiro NL (September 2006). "Interaction between warfarin and cranberry juice". <i>Pharmacotherapy</i> <b>26</b> (9): 1314–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1592%2Fphco.26.9.1314" class="external text" title="http://dx.doi.org/10.1592%2Fphco.26.9.1314" rel="nofollow">10.1592/phco.26.9.1314</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16945054" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16945054">PMID 16945054</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Interaction+between+warfarin+and+cranberry+juice&amp;rft.jtitle=Pharmacotherapy&amp;rft.aulast=Aston+JL%2C+Lodolce+AE%2C+Shapiro+NL&amp;rft.au=Aston+JL%2C+Lodolce+AE%2C+Shapiro+NL&amp;rft.date=September+2006&amp;rft.volume=26&amp;rft.issue=9&amp;rft.pages=1314%E2%80%939&amp;rft_id=info:doi/10.1592%2Fphco.26.9.1314&amp;rft_id=info:pmid/16945054&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span> <a href="http://www.medscape.com/viewarticle/545631" class="external text" title="http://www.medscape.com/viewarticle/545631" rel="nofollow">Free full text with registration at Medscape</a></li>
<li id="cite_note-Pham-52"><b><a href="#cite_ref-Pham_52-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFPham_DQ.2C_Pham_AQ2007">Pham DQ, Pham AQ (March 2007). "Interaction potential between cranberry juice and warfarin". <i>Am J Health Syst Pharm</i> <b>64</b> (5): 490–4. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.2146%2Fajhp060370" class="external text" title="http://dx.doi.org/10.2146%2Fajhp060370" rel="nofollow">10.2146/ajhp060370</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17322161" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17322161">PMID 17322161</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Interaction+potential+between+cranberry+juice+and+warfarin&amp;rft.jtitle=Am+J+Health+Syst+Pharm&amp;rft.aulast=Pham+DQ%2C+Pham+AQ&amp;rft.au=Pham+DQ%2C+Pham+AQ&amp;rft.date=March+2007&amp;rft.volume=64&amp;rft.issue=5&amp;rft.pages=490%E2%80%934&amp;rft_id=info:doi/10.2146%2Fajhp060370&amp;rft_id=info:pmid/17322161&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-53"><b><a href="#cite_ref-53" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREFUnited_States_.5B.5BOccupational_Safety_and_Health_Administration.5D.5D_.28OSHA.29">United States <a href="/wiki/Occupational_Safety_and_Health_Administration" title="Occupational Safety and Health Administration">Occupational Safety and Health Administration</a> (OSHA) (<span class="mw-formatted-date" title="1996-08-16"><span class="mw-formatted-date" title="08-16"><a href="/wiki/August_16" title="August 16">August 16</a></span>, <a href="/wiki/1996" title="1996">1996</a></span>). <a href="http://www.cdc.gov/Niosh/idlh/81812.html" class="external text" title="http://www.cdc.gov/Niosh/idlh/81812.html" rel="nofollow">"Documentation for Immediately Dangerous To Life or Health Concentrations (IDLHs): Warfarin"</a>. <a href="/wiki/Centers_for_Disease_Control_and_Prevention" title="Centers for Disease Control and Prevention">Centers for Disease Control and Prevention</a><span class="printonly">. <a href="http://www.cdc.gov/Niosh/idlh/81812.html" class="external free" title="http://www.cdc.gov/Niosh/idlh/81812.html" rel="nofollow">http://www.cdc.gov/Niosh/idlh/81812.html</a></span><span class="reference-accessdate">. Retrieved on 2008-07-07</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Documentation+for+Immediately+Dangerous+To+Life+or+Health+Concentrations+%28IDLHs%29%3A+Warfarin&amp;rft.atitle=&amp;rft.aulast=United+States+%5B%5BOccupational+Safety+and+Health+Administration%5D%5D+%28OSHA%29&amp;rft.au=United+States+%5B%5BOccupational+Safety+and+Health+Administration%5D%5D+%28OSHA%29&amp;rft.date=%5B%5BAugust+16%5D%5D%2C+%5B%5B1996%5D%5D&amp;rft.pub=%5B%5BCenters+for+Disease+Control+and+Prevention%5D%5D&amp;rft_id=http%3A%2F%2Fwww.cdc.gov%2FNiosh%2Fidlh%2F81812.html&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-NZToxins-54"><b><a href="#cite_ref-NZToxins_54-0" title="">^</a></b> <cite style="font-style:normal" class="book" id="CITEREFCharles_T._EasonMark_Wickstrom2001">Charles T. Eason; Mark Wickstrom (2001). <a href="http://www.doc.govt.nz/upload/documents/science-and-technical/docts23b.pdf" class="external text" title="http://www.doc.govt.nz/upload/documents/science-and-technical/docts23b.pdf" rel="nofollow">"2. Anticoagulant poisons"</a>. <i>Vertebrate pesticide toxicology manual (poisons)</i>. <a href="/wiki/Department_of_Conservation_(New_Zealand)" title="Department of Conservation (New Zealand)">New Zealand Department of Conservation</a>. pp.&#160;41–74. <a href="/wiki/Special:BookSources/0478220359" class="internal">ISBN 0-478-22035-9</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=2.+Anticoagulant+poisons&amp;rft.atitle=Vertebrate+pesticide+toxicology+manual+%28poisons%29&amp;rft.aulast=Charles+T.+Eason&amp;rft.au=Charles+T.+Eason&amp;rft.au=Mark+Wickstrom&amp;rft.date=2001&amp;rft.pages=pp.%26nbsp%3B41%E2%80%9374&amp;rft.pub=%5B%5BDepartment+of+Conservation+%28New+Zealand%29%7CNew+Zealand+Department+of+Conservation%5D%5D&amp;rft.isbn=0-478-22035-9&amp;rfr_id=info:sid/en.wikipedia.org:Warfarin"><span style="display: none;">&#160;</span></span></li>
</ol>
</div>
<p><a name="External_links" id="External_links"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Warfarin&amp;action=edit&amp;section=23" title="Edit section: External links">edit</a>]</span> <span class="mw-headline">External links</span></h2>
<ul>
<li><a href="http://www.warf.org/about/index.jsp?cid=26&amp;scid=34" class="external text" title="http://www.warf.org/about/index.jsp?cid=26&amp;scid=34" rel="nofollow">Historical information on Warfarin</a> from the <a href="/wiki/Wisconsin_Alumni_Research_Foundation" title="Wisconsin Alumni Research Foundation">Wisconsin Alumni Research Foundation</a></li>
</ul>
<table class="navbox" cellspacing="0" style=";">
<tr>
<td style="padding:2px;">
<table cellspacing="0" class="nowraplinks collapsible autocollapse" style="width:100%;background:transparent;color:inherit;;">
<tr>
<th style=";" colspan="2" class="navbox-title">
<div style="float:left; width:6em;text-align:left;">
<div class="noprint plainlinksneverexpand navbar" style="background:none; padding:0; font-weight:normal;;;border:none;; font-size:xx-small;"><a href="/wiki/Template:Antithrombotics" title="Template:Antithrombotics"><span title="View this template" style=";;border:none;">v</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<a href="/wiki/Template_talk:Antithrombotics" title="Template talk:Antithrombotics"><span title="Discussion about this template" style=";;border:none;">d</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<a href="http://en.wikipedia.org/w/index.php?title=Template:Antithrombotics&amp;action=edit" class="external text" title="http://en.wikipedia.org/w/index.php?title=Template:Antithrombotics&amp;action=edit" rel="nofollow"><span title="Edit this template" style=";;border:none;;">e</span></a></div>
</div>
<span style="font-size:110%;"><a href="/wiki/Antithrombotic" title="Antithrombotic">Antithrombotics</a> (<a href="/wiki/Thrombolytic_drug" title="Thrombolytic drug">thrombolytics</a>, <a href="/wiki/Anticoagulant" title="Anticoagulant">anticoagulants</a> and <a href="/wiki/Antiplatelet_drug" title="Antiplatelet drug">antiplatelet drugs</a>) (<a href="/wiki/ATC_code_B01" title="ATC code B01">B01</a>)</span></th>
</tr>
<tr style="height:2px;">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background:MistyRose;;"><a href="/wiki/Antiplatelet_drug" title="Antiplatelet drug">Antiplatelet drugs</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="width:100%;;;;">
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/Glycoprotein_IIb/IIIa_inhibitors" title="Glycoprotein IIb/IIIa inhibitors">Glycoprotein IIb/IIIa inhibitors</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Abciximab" title="Abciximab">Abciximab</a>&#160;• <a href="/wiki/Eptifibatide" title="Eptifibatide">Eptifibatide</a>&#160;• <a href="/wiki/Tirofiban" title="Tirofiban">Tirofiban</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/ADP_receptor" title="ADP receptor" class="mw-redirect">ADP receptor</a>/<a href="/wiki/P2Y12" title="P2Y12">P2Y<sub>12</sub></a> inhibitors</div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em">(<a href="/wiki/Thienopyridine" title="Thienopyridine">Thienopyridines</a>) <a href="/wiki/Clopidogrel" title="Clopidogrel">Clopidogrel</a>&#160;• <a href="/wiki/Ticlopidine" title="Ticlopidine">Ticlopidine</a>&#160;• <a href="/wiki/Prasugrel" title="Prasugrel">Prasugrel</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/Prostaglandin_analogue" title="Prostaglandin analogue">Prostaglandin analogue</a> (<a href="/wiki/Prostacyclin" title="Prostacyclin">PGI2</a>)</div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Beraprost" title="Beraprost">Beraprost</a>&#160;• <a href="/wiki/Prostacyclin" title="Prostacyclin">Prostacyclin</a>&#160;• <a href="/wiki/Iloprost" title="Iloprost">Iloprost</a>&#160;• <a href="/wiki/Treprostinil" title="Treprostinil">Treprostinil</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/Mechanism_of_action_of_aspirin" title="Mechanism of action of aspirin">COX inhibitors</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Aspirin" title="Aspirin">Acetylsalicylic acid/Aspirin</a>&#160;#&#160;• <a href="/wiki/Aloxiprin" title="Aloxiprin">Aloxiprin</a>&#160;• <a href="/wiki/Carbasalate_calcium" title="Carbasalate calcium">Carbasalate calcium</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;">Other</div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Ditazole" title="Ditazole">Ditazole</a>&#160;• <a href="/wiki/Cloricromen" title="Cloricromen">Cloricromen</a>&#160;• <a href="/wiki/Dipyridamole" title="Dipyridamole">Dipyridamole</a>&#160;• <a href="/wiki/Indobufen" title="Indobufen">Indobufen</a>&#160;• <a href="/wiki/Picotamide" title="Picotamide">Picotamide</a>&#160;• <a href="/wiki/Triflusal" title="Triflusal">Triflusal</a></div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background:MistyRose;;"><a href="/wiki/Anticoagulant" title="Anticoagulant">Anticoagulants</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="width:100%;;;;">
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/Vitamin_K_antagonist" title="Vitamin K antagonist">Vitamin K antagonists</a><br />
(inhibit <a href="/wiki/Thrombin" title="Thrombin">II</a>, <a href="/wiki/Factor_VII" title="Factor VII">VII</a>, <a href="/wiki/Factor_IX" title="Factor IX">IX</a>, <a href="/wiki/Factor_X" title="Factor X">X</a>)</div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><i><a href="/wiki/Coumarin" title="Coumarin">coumarins</a>:</i> <a href="/wiki/Acenocoumarol" title="Acenocoumarol">Acenocoumarol</a>&#160;• <a href="/wiki/Coumatetralyl" title="Coumatetralyl">Coumatetralyl</a>&#160;• <a href="/wiki/Dicoumarol" title="Dicoumarol">Dicoumarol</a> (Dicumarol)&#160;• <a href="/wiki/Ethyl_biscoumacetate" title="Ethyl biscoumacetate">Ethyl biscoumacetate</a>&#160;• <a href="/wiki/Phenprocoumon" title="Phenprocoumon">Phenprocoumon</a>&#160;• <strong class="selflink">Warfarin</strong>
<p><i><a href="/wiki/1,3-indandione" title="1,3-indandione" class="mw-redirect">1,3-indandiones</a>:</i> <a href="/wiki/Clorindione" title="Clorindione">Clorindione</a>&#160;• <a href="/wiki/Diphenadione" title="Diphenadione">Diphenadione</a>&#160;• <a href="/wiki/Phenindione" title="Phenindione">Phenindione</a></p>
<i>other:</i> <a href="/wiki/Tioclomarol" title="Tioclomarol">Tioclomarol</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/Factor_Xa" title="Factor Xa" class="mw-redirect">Factor Xa</a> inhibitors<br />
(with some II inhibition)</div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="width:100%;;;;">
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/Heparin" title="Heparin">Heparin</a> group/<br />
<a href="/wiki/Glycosaminoglycan" title="Glycosaminoglycan">glycosaminoglycans</a>/<br />
(bind <a href="/wiki/Antithrombin" title="Antithrombin">antithrombin</a>)</div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><i><a href="/wiki/Low_molecular_weight_heparin" title="Low molecular weight heparin">low molecular weight heparin</a></i> (<a href="/wiki/Bemiparin" title="Bemiparin" class="mw-redirect">Bemiparin</a>, <a href="/wiki/Certoparin" title="Certoparin" class="mw-redirect">Certoparin</a>, <a href="/wiki/Dalteparin" title="Dalteparin" class="mw-redirect">Dalteparin</a>, <a href="/wiki/Enoxaparin_sodium" title="Enoxaparin sodium">Enoxaparin</a>, <a href="/wiki/Nadroparin" title="Nadroparin" class="mw-redirect">Nadroparin</a>, <a href="/wiki/Parnaparin" title="Parnaparin" class="mw-redirect">Parnaparin</a>, <a href="/wiki/Reviparin" title="Reviparin" class="mw-redirect">Reviparin</a>, <a href="/wiki/Tinzaparin" title="Tinzaparin" class="mw-redirect">Tinzaparin</a>)
<p><i><a href="/wiki/Oligosaccharide" title="Oligosaccharide">oligosaccharides</a></i> (<a href="/wiki/Fondaparinux" title="Fondaparinux">Fondaparinux</a>, <a href="/wiki/Idraparinux" title="Idraparinux">Idraparinux</a>)</p>
<i><a href="/wiki/Heparinoid" title="Heparinoid">heparinoid</a></i> (<a href="/wiki/Danaparoid" title="Danaparoid">Danaparoid</a>, <a href="/wiki/Sulodexide" title="Sulodexide">Sulodexide</a>, <a href="/wiki/Dermatan_sulfate" title="Dermatan sulfate">Dermatan sulfate</a>)</div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/Direct_factor_Xa_inhibitor" title="Direct factor Xa inhibitor">Direct factor Xa inhibitors</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><i>xabans</i> (<a href="/wiki/Apixaban" title="Apixaban">Apixaban</a>, <a href="/wiki/Otamixaban" title="Otamixaban">Otamixaban</a>, <a href="/wiki/Rivaroxaban" title="Rivaroxaban">Rivaroxaban</a>)</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/Direct_thrombin_inhibitor" title="Direct thrombin inhibitor">Direct thrombin (II) inhibitors</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><i><a href="/wiki/Direct_thrombin_inhibitor#Bivalent" title="Direct thrombin inhibitor">bivalent</a>:</i> <a href="/wiki/Hirudin" title="Hirudin">Hirudin</a> (<a href="/wiki/Bivalirudin" title="Bivalirudin">Bivalirudin</a>, <a href="/wiki/Lepirudin" title="Lepirudin">Lepirudin</a>, <a href="/wiki/Desirudin" title="Desirudin" class="mw-redirect">Desirudin</a>)<br />
<i><a href="/wiki/Direct_thrombin_inhibitor#Univalent" title="Direct thrombin inhibitor">univalent</a>:</i> <a href="/wiki/Argatroban" title="Argatroban">Argatroban</a>&#160;• <a href="/wiki/Dabigatran" title="Dabigatran">Dabigatran</a>&#160;• <a href="/wiki/Melagatran" title="Melagatran" class="mw-redirect">Melagatran</a>&#160;• <a href="/wiki/Ximelagatran" title="Ximelagatran">Ximelagatran</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;">Other</div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Defibrotide" title="Defibrotide">Defibrotide</a>&#160;• <a href="/wiki/Ramatroban" title="Ramatroban">Ramatroban</a>&#160;• <a href="/wiki/Antithrombin" title="Antithrombin">Antithrombin III</a>&#160;• <a href="/wiki/Protein_C" title="Protein C">Protein C</a> (<a href="/wiki/Drotrecogin_alfa" title="Drotrecogin alfa">Drotrecogin alfa</a>)</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background:MistyRose;;"><a href="/wiki/Thrombolytic_drug" title="Thrombolytic drug">Thrombolytic drugs</a>/<br />
<a href="/wiki/Fibrinolytic" title="Fibrinolytic" class="mw-redirect">fibrinolytics</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><i><a href="/wiki/Plasminogen_activator" title="Plasminogen activator">plasminogen activators</a>:</i> <i>TPA</i> (<a href="/wiki/Tissue_plasminogen_activator" title="Tissue plasminogen activator">Alteplase</a>, <a href="/wiki/Reteplase" title="Reteplase">Reteplase</a>, <a href="/wiki/Tenecteplase" title="Tenecteplase">Tenecteplase</a>)&#160;• <i>UPA</i> (<a href="/wiki/Urokinase" title="Urokinase">Urokinase</a>, <a href="/wiki/Saruplase" title="Saruplase">Saruplase</a>)&#160;• <a href="/wiki/Streptokinase" title="Streptokinase">Streptokinase</a>&#160;#&#160;• <a href="/wiki/Anistreplase" title="Anistreplase">Anistreplase</a>&#160;• <a href="/wiki/Monteplase" title="Monteplase">Monteplase</a>
<p><i>other <a href="/wiki/Serine_endopeptidase" title="Serine endopeptidase" class="mw-redirect">serine endopeptidases</a>:</i> <a href="/wiki/Ancrod" title="Ancrod">Ancrod</a>&#160;• <a href="/wiki/Fibrinolysin" title="Fibrinolysin">Fibrinolysin</a></p>
<a href="/wiki/Brinase" title="Brinase">Brinase</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background:MistyRose;;"><a href="/wiki/Anticoagulant#Anticoagulants_outside_the_body" title="Anticoagulant">Non-medicinal</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Citrate" title="Citrate">Citrate</a>&#160;• <a href="/wiki/EDTA" title="EDTA">EDTA</a>&#160;• <a href="/wiki/Oxalate" title="Oxalate">Oxalate</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td colspan="2" style="width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><i># = <a href="/wiki/List_of_World_Health_Organization_Essential_Medicines" title="List of World Health Organization Essential Medicines">WHO-EM</a></i></div>
</td>
</tr>
</table>
</td>
</tr>
</table>


<!-- 
NewPP limit report
Preprocessor node count: 30143/1000000
Post-expand include size: 308380/2048000 bytes
Template argument size: 119099/2048000 bytes
Expensive parser function count: 1/500
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:238097-0!1!0!default!!en!2 and timestamp 20090403221243 -->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org/wiki/Warfarin">http://en.wikipedia.org/wiki/Warfarin</a>"</div>
			<div id='catlinks' class='catlinks'><div id="mw-normal-catlinks"><a href="/wiki/Special:Categories" title="Special:Categories">Categories</a>:&#32;<span dir='ltr'><a href="/wiki/Category:Anticoagulants" title="Category:Anticoagulants">Anticoagulants</a></span> | <span dir='ltr'><a href="/wiki/Category:Rodenticides" title="Category:Rodenticides">Rodenticides</a></span> | <span dir='ltr'><a href="/wiki/Category:Teratogens" title="Category:Teratogens">Teratogens</a></span> | <span dir='ltr'><a href="/wiki/Category:Lactones" title="Category:Lactones">Lactones</a></span></div><div id="mw-hidden-catlinks" class="mw-hidden-cats-hidden">Hidden categories:&#32;<span dir='ltr'><a href="/wiki/Category:All_articles_with_unsourced_statements" title="Category:All articles with unsourced statements">All articles with unsourced statements</a></span> | <span dir='ltr'><a href="/wiki/Category:Articles_with_unsourced_statements_since_January_2009" title="Category:Articles with unsourced statements since January 2009">Articles with unsourced statements since January 2009</a></span></div></div>			<!-- end content -->
						<div class="visualClear"></div>
		</div>
	</div>
		</div>
		<div id="column-one">
	<div id="p-cactions" class="portlet">
		<h5>Views</h5>
		<div class="pBody">
			<ul>
	
				 <li id="ca-nstab-main" class="selected"><a href="/wiki/Warfarin" title="View the content page [c]" accesskey="c">Article</a></li>
				 <li id="ca-talk"><a href="/wiki/Talk:Warfarin" title="Discussion about the content page [t]" accesskey="t">Discussion</a></li>
				 <li id="ca-edit"><a href="/w/index.php?title=Warfarin&amp;action=edit" title="You can edit this page. &#10;Please use the preview button before saving. [e]" accesskey="e">Edit this page</a></li>
				 <li id="ca-history"><a href="/w/index.php?title=Warfarin&amp;action=history" title="Past versions of this page [h]" accesskey="h">History</a></li>			</ul>
		</div>
	</div>
	<div class="portlet" id="p-personal">
		<h5>Personal tools</h5>
		<div class="pBody">
			<ul>
				<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Warfarin" title="You are encouraged to log in; however, it is not mandatory. [o]" accesskey="o">Log in / create account</a></li>
			</ul>
		</div>
	</div>
	<div class="portlet" id="p-logo">
		<a style="background-image: url(http://upload.wikimedia.org/wikipedia/en/b/bc/Wiki.png);" href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
	<div class='generated-sidebar portlet' id='p-navigation'>
		<h5>Navigation</h5>
		<div class='pBody'>
			<ul>
				<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li>
				<li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li>
				<li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content — the best of Wikipedia">Featured content</a></li>
				<li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li>
				<li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li>
			</ul>
		</div>
	</div>
	<div id="p-search" class="portlet">
		<h5><label for="searchInput">Search</label></h5>
		<div id="searchBody" class="pBody">
			<form action="/w/index.php" id="searchform"><div>
				<input type='hidden' name="title" value="Special:Search"/>
				<input id="searchInput" name="search" type="text" title="Search Wikipedia [f]" accesskey="f" value="" />
				<input type='submit' name="go" class="searchButton" id="searchGoButton"	value="Go" title="Go to a page with this exact name if one exists" />&nbsp;
				<input type='submit' name="fulltext" class="searchButton" id="mw-searchButton" value="Search" title="Search Wikipedia for this text" />
			</div></form>
		</div>
	</div>
	<div class='generated-sidebar portlet' id='p-interaction'>
		<h5>Interaction</h5>
		<div class='pBody'>
			<ul>
				<li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li>
				<li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li>
				<li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="The list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li>
				<li id="n-contact"><a href="/wiki/Wikipedia:Contact_us" title="How to contact Wikipedia">Contact Wikipedia</a></li>
				<li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Donate" title="Support us">Donate to Wikipedia</a></li>
				<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li>
			</ul>
		</div>
	</div>
	<div class="portlet" id="p-tb">
		<h5>Toolbox</h5>
		<div class="pBody">
			<ul>
				<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Warfarin" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li>
				<li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Warfarin" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li>
<li id="t-upload"><a href="/wiki/Wikipedia:Upload" title="Upload files [u]" accesskey="u">Upload file</a></li>
<li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</a></li>
				<li id="t-print"><a href="/w/index.php?title=Warfarin&amp;printable=yes" rel="alternate" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>				<li id="t-permalink"><a href="/w/index.php?title=Warfarin&amp;oldid=281584235" title="Permanent link to this version of the page">Permanent link</a></li><li id="t-cite"><a href="/w/index.php?title=Special:Cite&amp;page=Warfarin&amp;id=281584235">Cite this page</a></li>			</ul>
		</div>
	</div>
	<div id="p-lang" class="portlet">
		<h5>Languages</h5>
		<div class="pBody">
			<ul>
				<li class="interwiki-da"><a href="http://da.wikipedia.org/wiki/Warfarin">Dansk</a></li>
				<li class="interwiki-de"><a href="http://de.wikipedia.org/wiki/Warfarin">Deutsch</a></li>
				<li class="interwiki-es"><a href="http://es.wikipedia.org/wiki/Warfarina">Español</a></li>
				<li class="interwiki-fr"><a href="http://fr.wikipedia.org/wiki/Coumaph%C3%A8ne">Français</a></li>
				<li class="interwiki-it"><a href="http://it.wikipedia.org/wiki/Warfarin">Italiano</a></li>
				<li class="interwiki-he"><a href="http://he.wikipedia.org/wiki/%D7%A7%D7%95%D7%9E%D7%93%D7%99%D7%9F">עברית</a></li>
				<li class="interwiki-hu"><a href="http://hu.wikipedia.org/wiki/Warfarin">Magyar</a></li>
				<li class="interwiki-nl"><a href="http://nl.wikipedia.org/wiki/Coumarinederivaten">Nederlands</a></li>
				<li class="interwiki-ja"><a href="http://ja.wikipedia.org/wiki/%E3%83%AF%E3%83%AB%E3%83%95%E3%82%A1%E3%83%AA%E3%83%B3">日本語</a></li>
				<li class="interwiki-no"><a href="http://no.wikipedia.org/wiki/Warfarin">‪Norsk (bokmål)‬</a></li>
				<li class="interwiki-pl"><a href="http://pl.wikipedia.org/wiki/Warfaryna">Polski</a></li>
				<li class="interwiki-pt"><a href="http://pt.wikipedia.org/wiki/Varfarina">Português</a></li>
				<li class="interwiki-fi"><a href="http://fi.wikipedia.org/wiki/Varfariini">Suomi</a></li>
				<li class="interwiki-sv"><a href="http://sv.wikipedia.org/wiki/Warfarin">Svenska</a></li>
				<li class="interwiki-th"><a href="http://th.wikipedia.org/wiki/%E0%B8%A7%E0%B8%B2%E0%B8%A3%E0%B9%8C%E0%B8%9F%E0%B8%B2%E0%B8%A3%E0%B8%B4%E0%B8%99">ไทย</a></li>
				<li class="interwiki-tr"><a href="http://tr.wikipedia.org/wiki/Varfarin">Türkçe</a></li>
				<li class="interwiki-zh"><a href="http://zh.wikipedia.org/wiki/%E5%8D%8E%E6%B3%95%E6%9E%97">中文</a></li>
			</ul>
		</div>
	</div>
		</div><!-- end of the left (by default at least) column -->
			<div class="visualClear"></div>
			<div id="footer">
				<div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="/skins-1.5/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>
				<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="/images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>
			<ul id="f-list">
					<li id="lastmod"> This page was last modified on 3 April 2009, at 22:12.</li>
					<li id="copyright">All text is available under the terms of the <a class='internal' href="http://en.wikipedia.org/wiki/Wikipedia:Text_of_the_GNU_Free_Documentation_License" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="http://en.wikipedia.org/wiki/Wikipedia:Copyrights" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc.</a>, a U.S. registered <a class='internal' href="http://en.wikipedia.org/wiki/501%28c%29#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="http://en.wikipedia.org/wiki/Non-profit_organization" title="Non-profit organization">nonprofit</a> <a href="http://en.wikipedia.org/wiki/Charitable_organization" title="Charitable organization">charity</a>.<br /></li>
					<li id="privacy"><a href="http://wikimediafoundation.org/wiki/Privacy_policy" title="wikimedia:Privacy policy">Privacy policy</a></li>
					<li id="about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
					<li id="disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
			</ul>
		</div>
</div>

		<script type="text/javascript">if (window.runOnloadHook) runOnloadHook();</script>
<!-- Served by srv173 in 0.055 secs. --></body></html>
